{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T16:53:20Z","timestamp":1778172800482,"version":"3.51.4"},"reference-count":288,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Huntington\u2019s disease (HD), a neurodegenerative disease, typically begins in the prime of adulthood, followed by a gradual onset of specific mental abnormalities and cognitive and physical impairment. To the best of our knowledge, no medication exists to totally stop the progression of HD. Among numerous therapy techniques, extensive literature reviews have confirmed the medicinal importance of natural products in HD experimental models. This review provides a literature survey of natural compounds and medicinal plants used as neuroprotective agents against HD. Relevant studies were found in a variety of scientific databases, including PubMed, ScienceDirect, Scopus, and Google Scholar. Overall, natural products provided various levels of neuroprotection in preclinical HD investigations through antioxidant and anti-inflammatory activities, mitochondrial function maintenance, apoptosis suppression, and autophagy induction. Plants such as\n                    <jats:italic>Bacopa monnieri<\/jats:italic>\n                    ,\n                    <jats:italic>Ginkgo biloba<\/jats:italic>\n                    ,\n                    <jats:italic>Panax ginseng<\/jats:italic>\n                    , and\n                    <jats:italic>Withaniasomnifera<\/jats:italic>\n                    were identified as the most promising anti-HD possibilities, with several of them known as CNS-active medicines. Curcumin, epigallocatechin-gallate, ginsenosides, kaempferol, naringin, and resveratrol were identified as anti-HD compounds, some of which are well recognized neuroprotectants. Further study is required to assess the therapeutic efficacy of new herbal extracts in HD animals.\n                  <\/jats:p>","DOI":"10.1007\/s00210-025-04444-w","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T18:23:17Z","timestamp":1752776597000},"page":"16817-16847","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Natural products proposed for the management of Huntington\u2019s disease (HD): a comprehensive review"],"prefix":"10.1007","volume":"398","author":[{"given":"Aya","family":"Salman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya H.","family":"Eid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samar S.","family":"Khalaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed M.","family":"El-Dessouki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3179-3352","authenticated-orcid":false,"given":"Riham A.","family":"El-Shiekh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaza H.","family":"Aly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"key":"4444_CR1","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1039\/D3RA06355K","volume":"14","author":"EB Abdelazim","year":"2024","unstructured":"Abdelazim EB, Abed T, Goher SS, Alya SH, El-Nashar HA, El-Moslamy SH, El-Fakharany EM, Abdul-Baki EA, Shakweer MM, Eissa NG (2024) In vitro and in vivo studies of Syzygium cumini-loaded electrospun PLGA\/PMMA\/collagen nanofibers for accelerating topical wound healing. RSC Adv 14:101\u2013117","journal-title":"RSC Adv"},{"key":"4444_CR2","doi-asserted-by":"publisher","first-page":"117739281986641","DOI":"10.1177\/1177392819866412","volume":"13","author":"AS Abdul Manap","year":"2019","unstructured":"Abdul Manap AS, Vijayabalan S, Madhavan P, Chia YY, Arya A, Wong EH, Rizwan F, Bindal U, Koshy S (2019) Bacopa monnieri, a neuroprotective lead in Alzheimer disease: a review on its properties, mechanisms of action, and preclinical and clinical studies. Drug Target Insights 13:1177392819866412","journal-title":"Drug Target Insights"},{"key":"4444_CR3","doi-asserted-by":"crossref","unstructured":"Ahmed M, Mridha D (2023) Unraveling Huntington\u2019s disease: a report on genetic testing, clinical presentation, and disease progression. Cureus J Med Sci 15","DOI":"10.7759\/cureus.43377"},{"key":"4444_CR4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s10495-020-01645-x","volume":"26","author":"S Ahmed","year":"2021","unstructured":"Ahmed S, Kwatra M, Gawali B, Panda SR, Naidu VGM (2021) Potential role of TrkB agonist in neuronal survival by promoting CREB\/BDNF and PI3K\/Akt signaling in vitro and in vivo model of 3-nitropropionic acid (3-NP)-induced neuronal death. Apoptosis\u202f: an International Journal on Programmed Cell Death 26:52\u201370","journal-title":"Apoptosis : an International Journal on Programmed Cell Death"},{"key":"4444_CR5","doi-asserted-by":"crossref","unstructured":"Akila R, Shaji DM (2022) Ginger loaded chitosan nanoparticles for the management of 3\u2013Nitropropionic acid-induced Huntington\u2019s disease-like symptoms in male Wistar rats. Int J Pharm Pharm Sci 14:28\u201336","DOI":"10.22159\/ijpps.2022v14i1.42894"},{"key":"4444_CR6","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1179\/1476830514Y.0000000155","volume":"20","author":"BN Al-Sabahi","year":"2017","unstructured":"Al-Sabahi BN, Fatope MO, Essa MM, Subash S, Al-Busafi SN, Al-Kusaibi FSM, Manivasagam T (2017) Pomegranate seed oil: effect on 3-nitropropionic acid-induced neurotoxicity in PC12 cells and elucidation of unsaturated fatty acids composition. Nutr Neurosci 20:40\u201348","journal-title":"Nutr Neurosci"},{"key":"4444_CR7","doi-asserted-by":"publisher","first-page":"111039","DOI":"10.1016\/j.brainresbull.2024.111039","volume":"216","author":"A Aliaghaei","year":"2024","unstructured":"Aliaghaei A, Meftahi GH (2024) Silymarin ameliorates motor function and averts neuroinflammation-induced cell death in the rat model of Huntington\u2019s disease. Brain Res Bull 216:111039","journal-title":"Brain Res Bull"},{"key":"4444_CR8","doi-asserted-by":"crossref","unstructured":"Aly SH, El-Hassab MA, Elhady SS, Gad HA (2022) Comparative metabolic study of Tamarindus indica L.\u2019s various organs based on GC\/MS analysis, in silico and in vitro anti-inflammatory and wound healing activities. Plants 12: 87","DOI":"10.3390\/plants12010087"},{"key":"4444_CR9","doi-asserted-by":"publisher","first-page":"2292482","DOI":"10.1080\/14756366.2023.2292482","volume":"39","author":"SH Aly","year":"2024","unstructured":"Aly SH, Elissawy AM, El Hassab MA, Majrashi TA, Hassan FE, Elkaeed EB, Eldehna WM, Singab ANB (2024a) Comparative metabolic study of the chloroform fraction of three Cystoseira species based on UPLC\/ESI\/MS analysis and biological activities. J Enzyme Inhib Med Chem 39:2292482","journal-title":"J Enzyme Inhib Med Chem"},{"key":"4444_CR10","doi-asserted-by":"crossref","unstructured":"Aly SH, Kandil NH, Hemdan RM, Kotb SS, Zaki SS, Abdelaziz OM, AbdelRazek MM, Almahli H, El Hassab MA, Al-Rashood ST (2023) GC\/MS profiling of the essential oil and lipophilic extract of Moricandia sinaica Boiss. and evaluation of their cytotoxic and antioxidant activities. Mol 28: 2193","DOI":"10.3390\/molecules28052193"},{"key":"4444_CR11","doi-asserted-by":"publisher","first-page":"e0307901","DOI":"10.1371\/journal.pone.0307901","volume":"19","author":"SH Aly","year":"2024","unstructured":"Aly SH, Mahmoud AM, Abdel Mageed SS, Khaleel EF, Badi RM, Elkaeed EB, Rasheed RA, El Hassab MA, Eldehna WM (2024b) Exploring the phytochemicals, antioxidant properties, and hepatoprotective potential of Moricandia sinaica leaves against paracetamol-induced toxicity: Biological evaluations and in Silico insights. PLoS ONE 19:e0307901","journal-title":"PLoS ONE"},{"key":"4444_CR12","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/j.1527-3458.2001.tb00198.x","volume":"7","author":"SA Anttila","year":"2001","unstructured":"Anttila SA, Leinonen EV (2001) A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev 7:249\u2013264","journal-title":"CNS Drug Rev"},{"key":"4444_CR13","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1212\/WNL.0b013e318263c443","volume":"79","author":"MJ Armstrong","year":"2012","unstructured":"Armstrong MJ, Miyasaki JM (2012) Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology 79:597\u2013603","journal-title":"Neurology"},{"key":"4444_CR14","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1093\/brain\/awae023","volume":"147","author":"K Atkins","year":"2024","unstructured":"Atkins K, Andrews S, Stout J, Chong T (2024) The effect of Huntington\u2019s disease on cognitive and physical motivation. Brain 147:2449\u20132458","journal-title":"Brain"},{"key":"4444_CR15","doi-asserted-by":"publisher","first-page":"710","DOI":"10.3389\/fneur.2019.00710","volume":"10","author":"A-C Bachoud-L\u00e9vi","year":"2019","unstructured":"Bachoud-L\u00e9vi A-C, Ferreira J, Massart R, Youssov K, Rosser A, Busse M, Craufurd D, Reilmann R, De Michele G, Rae D (2019a) International guidelines for the treatment of Huntington\u2019s disease. Front Neurol 10:710","journal-title":"Front Neurol"},{"key":"4444_CR16","doi-asserted-by":"publisher","first-page":"710","DOI":"10.3389\/fneur.2019.00710","volume":"10","author":"AC Bachoud-L\u00e9vi","year":"2019","unstructured":"Bachoud-L\u00e9vi AC, Ferreira J, Massart R, Youssov K, Rosser A, Busse M, Craufurd D, Reilmann R, De Michele G, Rae D, Squitieri F, Seppi K, Perrine C, Scherer-Gagou C, Audrey O, Verny C, Burgunder JM (2019b) International guidelines for the treatment of Huntington\u2019s disease. Front Neurol 10:710","journal-title":"Front Neurol"},{"key":"4444_CR17","doi-asserted-by":"publisher","first-page":"12220","DOI":"10.3390\/ijms252212220","volume":"25","author":"M Balducci","year":"2024","unstructured":"Balducci M, P\u00e9rez JT, Del R\u00edo CT, P\u00e9rez MC, Carranza AdV, Gomez Escribano AP, V\u00e1zquez-Manrique RP, Tarozzi A (2024) Erucin, a Natural isothiocyanate, prevents polyglutamine-induced toxicity in Caenorhabditis elegans via aak-2\/AMPK and daf-16\/FOXO signaling. Int J Mol Sci 25:12220","journal-title":"Int J Mol Sci"},{"key":"4444_CR18","doi-asserted-by":"crossref","unstructured":"Banerjee S, Tudu CK, Nandy S, Pandey DK, Ghorai M, Shekhawat MS, Ghosh A, Nongdam P, Al-Tawaha AR, Bursal E (2022) Herbal remedies against Huntington\u2019s disease: preclinical evidences and future directions. Herbal Medicines. Elsevier, pp. 37\u201369","DOI":"10.1016\/B978-0-323-90572-5.00010-X"},{"key":"4444_CR19","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1038\/s41374-018-0166-9","volume":"99","author":"S Baskota","year":"2019","unstructured":"Baskota S, Lopez O, Greenamyre J, Kofler J (2019) Spectrum of tau pathologies in Huntington\u2019s disease. Lab Invest 99:1068\u20131077","journal-title":"Lab Invest"},{"key":"4444_CR20","doi-asserted-by":"crossref","unstructured":"Bates G, Dorsey R, Gusella J, Hayden M, Kay C, Leavitt B, Nance M, Ross C, Scahill R, Wetzel R, Wild E, Tabrizi S (2015) Huntington disease. Nat Rev Dis Prim 1","DOI":"10.1038\/nrdp.2015.5"},{"key":"4444_CR21","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/mds.25750","volume":"29","author":"LJ Beglinger","year":"2014","unstructured":"Beglinger LJ, Adams WH, Langbehn D, Fiedorowicz JG, Jorge R, Biglan K, Caviness J, Olson B, Robinson RG, Kieburtz K, Paulsen JS (2014) Results of the citalopram to enhance cognition in Huntington disease trial. Movement Disorders\u202f: Official Journal of the Movement Disorder Society 29:401\u2013405","journal-title":"Movement Disorders : Official Journal of the Movement Disorder Society"},{"key":"4444_CR22","unstructured":"Begum AU, Fathima J (2020) Huntington\u2019s Disease: a rare neurodegerative disorder."},{"key":"4444_CR23","doi-asserted-by":"crossref","unstructured":"Benraiss A, Wang S, Herrlinger S, Li X, Chandler-Militello D, Mauceri J, Burm HB, Toner M, Osipovitch M, Jim Xu QJNc (2016) Human glia can both induce and rescue aspects of disease phenotype in Huntington disease. 7: 11758","DOI":"10.1038\/ncomms11758"},{"key":"4444_CR24","doi-asserted-by":"crossref","unstructured":"Bhat A, Moglad E, Afzal M, Thapa R, Almalki W, Kazmi I, Alzarea S, Ali H, Pant K, Singh T, Dureja H, Singh S, Dua K, Gupta G, Subramaniyan V (2024) Therapeutic approaches targeting aging and cellular senescence in Huntington\u2019s disease. Cns Neurosci Ther 30","DOI":"10.1111\/cns.70053"},{"key":"4444_CR25","doi-asserted-by":"crossref","unstructured":"Bhattacharyya A, Trotta CR, Narasimhan J, Wiedinger KJ, Li W, Effenberger KA, Woll MG, Jani MB, Risher N, Yeh SJNc (2021) Small molecule splicing modifiers with systemic HTT-lowering activity. 12: 7299","DOI":"10.1038\/s41467-021-27157-z"},{"key":"4444_CR26","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.3390\/biomedicines10123021","volume":"10","author":"MN Bin-Jumah","year":"2022","unstructured":"Bin-Jumah MN, Gilani SJ, Alabbasi AF, Al-Abbasi FA, AlGhamdi SA, Alshehri OY, Alghamdi AM, Sayyed N, Kazmi I (2022) Protective effect of Fustin against Huntington\u2019s disease in 3-Nitropropionic treated rats via downregulation of oxidative stress and alteration in neurotransmitters and brain-derived neurotrophic factor activity. Biomedicines 10:3021","journal-title":"Biomedicines"},{"key":"4444_CR27","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3389\/fncel.2020.00146","volume":"14","author":"A Bj\u00f6rklund","year":"2020","unstructured":"Bj\u00f6rklund A, Parmar M (2020) Neuronal replacement as a tool for basal ganglia circuitry repair: 40 years in perspective. Front Cell Neurosci 14:146","journal-title":"Front Cell Neurosci"},{"key":"4444_CR28","doi-asserted-by":"crossref","unstructured":"Blum D, Gall D, Cuvelier L, Schiffmann SNJN (2001) Topological analysis of striatal lesions induced by 3-nitropropionic acid in the Lewis rat. 12: 1769\u20131772","DOI":"10.1097\/00001756-200106130-00050"},{"key":"4444_CR29","doi-asserted-by":"crossref","unstructured":"Bollen E,\u00a0Prickaerts J (2012) Phosphodiesterases in neurodegenerative disorders. IUBMB life 64:965\u2013970","DOI":"10.1002\/iub.1104"},{"key":"4444_CR30","first-page":"1629","volume":"69","author":"YM Bordelon","year":"1997","unstructured":"Bordelon YM, Chesselet MF, Nelson D, Welsh F (1997) Ereci\u0144ska MJJon. Energetic Dysfunction in Quinolinic Acid-Lesioned Rat Striatum 69:1629\u20131639","journal-title":"Energetic Dysfunction in Quinolinic Acid-Lesioned Rat Striatum"},{"key":"4444_CR31","doi-asserted-by":"crossref","unstructured":"Borlongan CV, Koutouzis TK, Freeman TB, Hauser RA, Cahill DW, Sanberg PRJBRP (1997) Hyperactivity and hypoactivity in a rat model of Huntington\u2019s disease: the systemic 3-nitropropionic acid model. 1: 253\u2013257","DOI":"10.1016\/S1385-299X(96)00037-2"},{"key":"4444_CR32","first-page":"206","volume":"27","author":"JA Bouwens","year":"2015","unstructured":"Bouwens JA, van Duijn E, van der Mast RC, Roos RA (2015) Giltay EJJTJon, neurosciences c. Irritability in a Prospective Cohort of Huntington\u2019s Disease Mutation Carriers 27:206\u2013212","journal-title":"Irritability in a Prospective Cohort of Huntington\u2019s Disease Mutation Carriers"},{"key":"4444_CR33","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S0076-6879(06)12016-9","volume":"412","author":"HR Brignull","year":"2006","unstructured":"Brignull HR, Morley JF, Garcia SM, Morimoto RI (2006) Modeling polyglutamine pathogenesis in C. elegans. Methods Enzymol 412:256\u2013282","journal-title":"Methods Enzymol"},{"key":"4444_CR34","first-page":"7105","volume":"92","author":"E Brouillet","year":"1995","unstructured":"Brouillet E, Hantraye P, Ferrante RJ, Dolan R, Leroy-Willig A, Kowall NW (1995) Beal MFJPotNAoS. Chronic Mitochondrial Energy Impairment Produces Selective Striatal Degeneration and Abnormal Choreiform Movements in Primates 92:7105\u20137109","journal-title":"Chronic Mitochondrial Energy Impairment Produces Selective Striatal Degeneration and Abnormal Choreiform Movements in Primates"},{"key":"4444_CR35","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1002\/mds.22376","volume":"24","author":"L Brusa","year":"2009","unstructured":"Brusa L, Orlacchio A, Moschella V, Iani C, Bernardi G, Mercuri NB (2009) Treatment of the symptoms of Huntington\u2019s disease: preliminary results comparing aripiprazole and tetrabenazine. Movement Disorders\u202f: Official Journal of the Movement Disorder Society 24:126\u2013129","journal-title":"Movement Disorders : Official Journal of the Movement Disorder Society"},{"key":"4444_CR36","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/cns.12834","volume":"24","author":"A Cardinale","year":"2018","unstructured":"Cardinale A, Fusco FR (2018) Inhibition of phosphodiesterases as a strategy to achieve neuroprotection in Huntington\u2019s disease. CNS Neurosci Ther 24:319\u2013328","journal-title":"CNS Neurosci Ther"},{"key":"4444_CR37","doi-asserted-by":"publisher","first-page":"e0122335","DOI":"10.1371\/journal.pone.0122335","volume":"10","author":"AW Chan","year":"2015","unstructured":"Chan AW, Jiang J, Chen Y, Li C, Prucha MS, Hu Y, Chi T, Moran S, Rahim T, Li S (2015) Progressive cognitive deficit, motor impairment and striatal pathology in a transgenic Huntington disease monkey model from infancy to adulthood. PLoS ONE 10:e0122335","journal-title":"PLoS ONE"},{"key":"4444_CR38","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.neuro.2017.01.005","volume":"61","author":"T Chao","year":"2017","unstructured":"Chao T, Hu J, Pringsheim T (2017) Risk factors for the onset and progression of Huntington disease. Neurotoxicology 61:79\u201399","journal-title":"Neurotoxicology"},{"key":"4444_CR39","doi-asserted-by":"crossref","unstructured":"Chapron K, Lapointe P, Lessard I, Darsmstadt-Belanger H, Bouchard K, Gagnon C, Lavoie M, Duchesne E, Gaboury SJIA (2021) Acti-DM1: monitoring the activity level of people with myotonic dystrophy type 1 through activity and exercise recognition. 9: 49960\u201349973","DOI":"10.1109\/ACCESS.2021.3068877"},{"key":"4444_CR40","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12974-022-02419-9","volume":"19","author":"KP Chen","year":"2022","unstructured":"Chen KP, Hua KF, Tsai FT, Lin TY, Cheng CY, Yang DI, Hsu HT, Ju TC (2022) A selective inhibitor of the NLRP3 inflammasome as a potential therapeutic approach for neuroprotection in a transgenic mouse model of Huntington\u2019s disease. J Neuroinflammation 19:56","journal-title":"J Neuroinflammation"},{"key":"4444_CR41","doi-asserted-by":"crossref","unstructured":"Cherry JA, Davis RL (1999) Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and affect.\u00a0J Comp Neurol 407:287\u2013301","DOI":"10.1002\/(SICI)1096-9861(19990503)407:2<287::AID-CNE9>3.3.CO;2-I"},{"key":"4444_CR42","first-page":"809","volume":"17","author":"KJ Chien","year":"2018","unstructured":"Chien KJ, Horng CT, Huang YS, Hsieh YH, Wang CJ, Yang JS, Lu CC, Chen FA (2018) Effects of Lycium barbarum (goji berry) on dry eye disease in rats. Mol Med Rep 17:809\u2013818","journal-title":"Mol Med Rep"},{"key":"4444_CR43","doi-asserted-by":"publisher","first-page":"63","DOI":"10.31300\/TDB.14.2021.63-72","volume":"14","author":"CL Coe","year":"2021","unstructured":"Coe CL, Lubach GR (2021) Maternal determinants of gestation length in the rhesus monkey. Trends in Developmental Biology 14:63","journal-title":"Trends in Developmental Biology"},{"key":"4444_CR44","first-page":"936","volume":"16","author":"G Colpo","year":"2017","unstructured":"Colpo G, Rocha N, Stimming E, Teixeira A (2017) Immunomodulatory strategies for Huntington\u2019s disease treatment. CNS & Neurological Disorders-drug Targets 16:936\u2013944","journal-title":"CNS & Neurological Disorders-drug Targets"},{"key":"4444_CR45","doi-asserted-by":"crossref","unstructured":"Colwell CS,\u00a0 Levine MS (1995) Excitatory Synaptic Transmission in Neostriatal Neurons: Regulation by Cyclic AMP-Dependent Mechanisms.\u00a0J Neurosci\u00a015:1704\u20131713","DOI":"10.1523\/JNEUROSCI.15-03-01704.1995"},{"key":"4444_CR46","doi-asserted-by":"publisher","first-page":"E762","DOI":"10.1073\/pnas.1715865115","volume":"115","author":"P Conforti","year":"2018","unstructured":"Conforti P, Besusso D, Bocchi V, Faedo A, Cesana E, Rossetti G, Ranzani V, Svendsen C, Thompson L, Toselli M (2018) Faulty neuronal determination and cell polarization are reverted by modulating HD early phenotypes. Proc Natl Acad Sci 115:E762\u2013E771","journal-title":"Proc Natl Acad Sci"},{"key":"4444_CR47","doi-asserted-by":"crossref","unstructured":"Cong Y, Shintani M, Imanari F, Osada N, Endo TJOAJoIB (2022) A new approach to drug repurposing with two-stage prediction, machine learning, and unsupervised clustering of gene expression. 26: 339\u2013347","DOI":"10.1089\/omi.2022.0026"},{"key":"4444_CR48","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1176\/appi.neuropsych.21070191","volume":"35","author":"M Connors","year":"2023","unstructured":"Connors M, Teixeira-Pinto A, Loy C (2023) Apathy and depression in Huntington\u2019s disease: distinct longitudinal trajectories and clinical correlates. J Neuropsychiatr Clin Neurosci 35:69\u201376","journal-title":"J Neuropsychiatr Clin Neurosci"},{"key":"4444_CR49","doi-asserted-by":"publisher","first-page":"111323","DOI":"10.1016\/j.fct.2020.111323","volume":"141","author":"LM Cordeiro","year":"2020","unstructured":"Cordeiro LM, Machado ML, da Silva AF, Baptista FBO, da Silveira TL, Soares FAA, Arantes LP (2020) Rutin protects Huntington\u2019s disease through the insulin\/IGF1 (IIS) signaling pathway and autophagy activity: study in Caenorhabditis elegans model. Food Chem Toxicol 141:111323","journal-title":"Food Chem Toxicol"},{"key":"4444_CR50","doi-asserted-by":"publisher","first-page":"723431","DOI":"10.1155\/2015\/723431","volume":"2015","author":"AA Courtes","year":"2015","unstructured":"Courtes AA, Arantes LP, Barcelos RP, da Silva IK, Boligon AA, Athayde ML, Puntel RL, Soares FA (2015) Protective Effects of aqueous extract of Luehea divaricata against behavioral and oxidative changes induced by 3-nitropropionic acid in rats. Evid Based Complement Alternat Med 2015:723431","journal-title":"Evid Based Complement Alternat Med"},{"key":"4444_CR51","first-page":"219","volume":"14","author":"D Craufurd","year":"2001","unstructured":"Craufurd D, Thompson J, Snowden J (2001) Behavioral changes in Huntington disease. NEUROPSYCHIATRY NEUROPSYCHOLOGY AND BEHAVIORAL NEUROLOGY 14:219\u2013226","journal-title":"NEUROPSYCHIATRY NEUROPSYCHOLOGY AND BEHAVIORAL NEUROLOGY"},{"key":"4444_CR52","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3233\/JHD-140139","volume":"4","author":"E Cubo","year":"2015","unstructured":"Cubo E, Rivadeneyra J, Armesto D, Mariscal N, Martinez A, Camara R, Huntingto SME (2015) Relationship between nutritional status and the severity of Huntington\u2019s disease. A Spanish multicenter dietary intake study. JOURNAL OF HUNTINGTONS DISEASE 4:75\u201385","journal-title":"JOURNAL OF HUNTINGTONS DISEASE"},{"key":"4444_CR53","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.fct.2018.08.028","volume":"121","author":"J Cui","year":"2018","unstructured":"Cui J, Wang G, Kandhare AD, Mukherjee-Kandhare AA, Bodhankar SL (2018) Neuroprotective effect of naringin, a flavone glycoside in quinolinic acid-induced neurotoxicity: possible role of PPAR-\u03b3, Bax\/Bcl-2, and caspase-3. Food Chem Toxicol 121:95\u2013108","journal-title":"Food Chem Toxicol"},{"key":"4444_CR54","doi-asserted-by":"publisher","first-page":"9295","DOI":"10.1002\/fsn3.4505","volume":"12","author":"G Cusumano","year":"2024","unstructured":"Cusumano G, Flores GA, Cetiz MV, Kurt U, Ak G, Saka E, Aly SH, Eldahshan OA, Singab AN, Zengin G (2024) Small steps to the big picture for health-promoting applications through the use of chickweed (Stellaria media): in vitro, in silico, and pharmacological network approaches. Food Sci Nutr 12:9295\u20139313","journal-title":"Food Sci Nutr"},{"key":"4444_CR55","doi-asserted-by":"crossref","unstructured":"D\u2019Egidio F, Castelli V, Lombardozzi G, Ammannito F, Cimini A, d\u2019Angelo M (2024) Therapeutic advances in neural regeneration for Huntington\u2019s disease. Neural Regen Res 19:1991\u20131997","DOI":"10.4103\/1673-5374.390969"},{"key":"4444_CR56","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.biopha.2018.06.079","volume":"105","author":"RCSR Danduga","year":"2018","unstructured":"Danduga RCSR, Dondapati SR, Kola PK, Grace L, Tadigiri RVB, Kanakaraju VK (2018) Neuroprotective activity of tetramethylpyrazine against 3-nitropropionic acid induced Huntington\u2019s disease-like symptoms in rats. Biomed Pharmacother 105:1254\u20131268","journal-title":"Biomed Pharmacother"},{"key":"4444_CR57","doi-asserted-by":"crossref","unstructured":"Dar NJ, Ahmad M (2020) Neurodegenerative diseases and Withania somnifera (L.): an update. J ethnopharmacol 256: 112769","DOI":"10.1016\/j.jep.2020.112769"},{"key":"4444_CR58","doi-asserted-by":"crossref","unstructured":"Dar NJ, Bhat SA, Rehman MU, Booker A (2023) Investigating the molecular targets and therapeutic potential of Withania somnifera (Ashwagandha) in various pathophysiological conditions. Frontiers Media SA, p. 1187334","DOI":"10.3389\/fphar.2023.1187334"},{"key":"4444_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.hermed.2015.01.002","volume":"5","author":"A Dey","year":"2015","unstructured":"Dey A, De JN (2015) Neuroprotective therapeutics from botanicals and phytochemicals against Huntington\u2019s disease and related neurodegenerative disorders. Journal of Herbal Medicine 5:1\u201319","journal-title":"Journal of Herbal Medicine"},{"key":"4444_CR60","doi-asserted-by":"publisher","first-page":"626028","DOI":"10.1155\/2015\/626028","volume":"2015","author":"C Dhanalakshmi","year":"2015","unstructured":"Dhanalakshmi C, Manivasagam T, Nataraj J, Justin Thenmozhi A, Essa MM (2015) Neurosupportive role of vanillin, a natural phenolic compound, on rotenone induced neurotoxicity in SH-SY5Y neuroblastoma cells. Evidence-Based Complementary and Alternative Medicine 2015:626028","journal-title":"Evidence-Based Complementary and Alternative Medicine"},{"key":"4444_CR61","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/ajmg.a.38494","volume":"176","author":"AS Dickey","year":"2018","unstructured":"Dickey AS, La Spada AR (2018) Therapy development in Huntington disease: from current strategies to emerging opportunities. Am J Med Genet A 176:842\u2013861","journal-title":"Am J Med Genet A"},{"key":"4444_CR62","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/ana.21569","volume":"65","author":"V Drouet","year":"2009","unstructured":"Drouet V, Perrin V, Hassig R, Dufour N, Auregan G, Alves S, Bonvento G, Brouillet E, Luthi-Carter R, Hantraye P, D\u00e9glon N (2009) Sustained effects of nonallele-specific Huntingtin silencing. Ann Neurol 65:276\u2013285","journal-title":"Ann Neurol"},{"key":"4444_CR63","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.biopsych.2006.11.034","volume":"62","author":"K Duff","year":"2007","unstructured":"Duff K, Paulsen JS, Beglinger LJ, Langbehn DR, Stout JC (2007) Psychiatric symptoms in Huntington\u2019s disease before diagnosis: the predict-HD study. Biol Psychiat 62:1341\u20131346","journal-title":"Biol Psychiat"},{"key":"4444_CR64","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1186\/s12906-024-04670-4","volume":"24","author":"RH El Din","year":"2024","unstructured":"El Din RH, Thabit S (2024) Quinic acid protects against the development of Huntington\u2019s disease in Caenorhabditis elegans model. BMC Complementary Medicine and Therapies 24:377","journal-title":"BMC Complementary Medicine and Therapies"},{"key":"4444_CR65","first-page":"4012","volume":"28","author":"F Elifani","year":"2019","unstructured":"Elifani F, Amico E, Pepe G, Capocci L, Castaldo S, Rosa P, Montano E, Pollice A, Madonna M, Filosa S, Calogero A, Maglione V, Crispi S, Di Pardo A (2019) Curcumin dietary supplementation ameliorates disease phenotype in an animal model of Huntington\u2019s disease. Hum Mol Genet 28:4012\u20134021","journal-title":"Hum Mol Genet"},{"key":"4444_CR66","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.biopsych.2019.12.010","volume":"87","author":"N Ellis","year":"2020","unstructured":"Ellis N, Tee A, McAllister B, Massey T, McLauchlan D, Stone T, Correia K, Loupe J, Kim K, Barker D, Hong E, Chao M, Long J, Lucente D, Vonsattel J, Pinto R, Abu Elneel K, Ramos E, Mysore J, Gillis T, Wheeler V, Medway C, Hall L, Kwak S, Sampaio C, Ciosi M, Maxwell A, Chatzi A, Monckton D, Orth M, Landwehrmeyer G, Paulsen J, Shoulson I, Myers R, van Duijn E, Rickards H, MacDonald M, Lee J, Gusella J, Jones L, Holmans P (2020) Genetic risk underlying psychiatric and cognitive symptoms in Huntington\u2019s disease. Biol Psychiat 87:857\u2013865","journal-title":"Biol Psychiat"},{"key":"4444_CR67","doi-asserted-by":"publisher","first-page":"4947","DOI":"10.1038\/s41598-017-04990-1","volume":"7","author":"G Ellrichmann","year":"2017","unstructured":"Ellrichmann G, Blusch A, Fatoba O, Brunner J, Reick C, Hayardeny L, Hayden M, Sehr D, Winklhofer KF, Saft C, Gold R (2017) Laquinimod treatment in the R6\/2 mouse model. Sci Rep 7:4947","journal-title":"Sci Rep"},{"key":"4444_CR68","first-page":"440","volume":"9","author":"S Esmail","year":"2021","unstructured":"Esmail S, Danter WRJB (2021) Artificially Induced Pluripotent Stem Cell-Derived Whole-Brain Organoid for Modelling the Pathophysiology of Metachromatic Leukodystrophy and Drug Repurposing 9:440","journal-title":"Artificially Induced Pluripotent Stem Cell-Derived Whole-Brain Organoid for Modelling the Pathophysiology of Metachromatic Leukodystrophy and Drug Repurposing"},{"key":"4444_CR69","doi-asserted-by":"crossref","unstructured":"Faber PW, Alter Jr Fau - MacDonald ME, MacDonald Me Fau - Hart AC, Hart AC (1999) Polyglutamine-mediated dysfunction and apoptotic death of a Caenorhabditis elegans sensory neuron.","DOI":"10.1073\/pnas.96.1.179"},{"key":"4444_CR70","doi-asserted-by":"publisher","first-page":"146561","DOI":"10.1016\/j.brainres.2019.146561","volume":"1727","author":"I Faravelli","year":"2020","unstructured":"Faravelli I, Costamagna G, Tamanini S, Corti S (2020) Back to the origins: human brain organoids to investigate neurodegeneration. Brain Res 1727:146561","journal-title":"Brain Res"},{"key":"4444_CR71","doi-asserted-by":"publisher","first-page":"972379","DOI":"10.3389\/fnut.2022.972379","volume":"9","author":"U Fatima","year":"2022","unstructured":"Fatima U, Roy S, Ahmad S, Ali S, Elkady WM, Khan I, Alsaffar RM, Adnan M, Islam A, Hassan MI (2022) Pharmacological attributes of Bacopa monnieri extract: current updates and clinical manifestation. Front Nutr 9:972379","journal-title":"Front Nutr"},{"key":"4444_CR72","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1038\/s41591-022-01919-8","volume":"28","author":"A Feigin","year":"2022","unstructured":"Feigin A, Evans EE, Fisher TL, Leonard JE, Smith ES, Reader A, Mishra V, Manber R, Walters KA, Kowarski L, Oakes D, Siemers E, Kieburtz KD, Zauderer M (2022) Pepinemab antibody blockade of SEMA4D in early Huntington\u2019s disease: a randomized, placebo-controlled, phase 2 trial. Nat Med 28:2183\u20132193","journal-title":"Nat Med"},{"key":"4444_CR73","doi-asserted-by":"crossref","unstructured":"Field SE, Curle AJ, Barker RAJEOoID (2024) Inflammation and Huntington\u2019s disease-a neglected therapeutic target?","DOI":"10.1080\/13543784.2024.2348738"},{"key":"4444_CR74","doi-asserted-by":"publisher","first-page":"114585","DOI":"10.1016\/j.bbr.2023.114585","volume":"452","author":"B Firouzan","year":"2023","unstructured":"Firouzan B, Iravanpour F, Abbaszadeh F, Akparov V, Zaringhalam J, Ghasemi R, Maghsoudi N (2023) Dipeptide mimetic of BDNF ameliorates motor dysfunction and striatal apoptosis in 6-OHDA-induced Parkinson\u2019s rat model: considering Akt and MAPKs signaling. Behav Brain Res 452:114585","journal-title":"Behav Brain Res"},{"key":"4444_CR75","first-page":"59","volume":"26","author":"WW Fleischhacker","year":"1992","unstructured":"Fleischhacker WW, Hinterhuber H, Bauer H, Pflug B, Berner P, Simhandl C, Wolf R, Gerlach W, Jaklitsch H, Sastre-y-Hernandez MJN (1992) A Multicenter Double-Blind Study of Three Different Doses of the New cAMP-Phosphodiesterase Inhibitor Rolipram in Patients with Major Depressive Disorder 26:59\u201364","journal-title":"A Multicenter Double-Blind Study of Three Different Doses of the New cAMP-Phosphodiesterase Inhibitor Rolipram in Patients with Major Depressive Disorder"},{"key":"4444_CR76","doi-asserted-by":"crossref","unstructured":"Foksinska A, Crowder CM, Crouse AB, Henrikson J, Byrd WE, Rosenblatt G, Patton MJ, He K, Tran-Nguyen TK, Zheng MJFiAI (2022) The precision medicine process for treating rare disease using the artificial intelligence tool mediKanren. 5: 910216","DOI":"10.3389\/frai.2022.910216"},{"key":"4444_CR77","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s40263-022-00956-8","volume":"36","author":"S Frank","year":"2022","unstructured":"Frank S, Testa C, Edmondson MC, Goldstein J, Kayson E, Leavitt BR, Oakes D, O\u2019Neill C, Vaughan C, Whaley J, Gross N, Gordon MF, Savola JM (2022) The safety of deutetrabenazine for chorea in Huntington disease: an open-label extension study. CNS Drugs 36:1207\u20131216","journal-title":"CNS Drugs"},{"key":"4444_CR78","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/j.1365-2710.2007.00829.x","volume":"32","author":"T Fukasawa","year":"2007","unstructured":"Fukasawa T, Suzuki A, Otani K (2007) Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines. J Clin Pharm Ther 32:333\u2013341","journal-title":"J Clin Pharm Ther"},{"key":"4444_CR79","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1017\/S0317167100040427","volume":"22","author":"S Furtado","year":"1995","unstructured":"Furtado S, Suchowersky O (1995) Huntington\u2019s disease: recent advances in diagnosis and management. The Canadian Journal of Neurological Sciences Le Journal Canadien des Sciences Neurologiques 22:5\u201312","journal-title":"The Canadian Journal of Neurological Sciences Le Journal Canadien des Sciences Neurologiques"},{"key":"4444_CR80","doi-asserted-by":"publisher","first-page":"100091","DOI":"10.1016\/j.bbii.2024.100091","volume":"8","author":"DD Gadade","year":"2024","unstructured":"Gadade DD, Sareen R, Jain N, Shah K, Kumar V, Modi A, Chauhan NS (2024) Pharmacology of natural bioactive compounds used for management of Huntington diseases: an overview. Brain Behavior and Immunity Integrative 8:100091","journal-title":"Brain Behavior and Immunity Integrative"},{"key":"4444_CR81","doi-asserted-by":"publisher","first-page":"E227","DOI":"10.1097\/RLU.0b013e31828162cd","volume":"39","author":"J Gamez","year":"2014","unstructured":"Gamez J, Lorenzo-Bosquet C, Cuberas-Borr\u00f3s G, Carmona F, Bad\u00eda M, Castill\u00f3 J, Bad\u00eda M, de Fabregues O, Hern\u00e1ndez-Vara J, Castell-Conesa J (2014) Progressive presynaptic dopaminergic deterioration in huntington disease: a [123I]-FP-CIT SPECT two-year follow-up study. Clin Nucl Med 39:E227\u2013E228","journal-title":"Clin Nucl Med"},{"key":"4444_CR82","doi-asserted-by":"crossref","unstructured":"Ganesh S, Chithambaram T, Krishnan N, Vincent D, Kaliappan J, Srinivasan K (2023) Exploring Huntington\u2019s disease diagnosis via artificial intelligence models: a comprehensive review. Diagn 13","DOI":"10.3390\/diagnostics13233592"},{"key":"4444_CR83","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/aps.2014.107","volume":"36","author":"Y Gao","year":"2015","unstructured":"Gao Y, Chu S-f, Li J-p, Zhang Z, Yan J-q, Wen Z-l, Xia C-y, Mou Z, Wang Z-z, He W-b (2015) Protopanaxtriol protects against 3-nitropropionic acid-induced oxidative stress in a rat model of Huntington\u2019s disease. Acta Pharmacol Sin 36:311\u2013322","journal-title":"Acta Pharmacol Sin"},{"key":"4444_CR84","first-page":"3144","volume":"26","author":"G Garc\u00eda-D\u00edaz Barriga","year":"2017","unstructured":"Garc\u00eda-D\u00edaz Barriga G, Giralt A, Anglada-Huguet M, Gaja-Capdevila N, Orlandi JG, Soriano J, Canals JM, Alberch J (2017) 7,8-dihydroxyflavone ameliorates cognitive and motor deficits in a Huntington\u2019s disease mouse model through specific activation of the PLC\u03b31 pathway. Hum Mol Genet 26:3144\u20133160","journal-title":"Hum Mol Genet"},{"key":"4444_CR85","doi-asserted-by":"crossref","unstructured":"Garcia-Gonzalez X, Cubo E, Simon-Vicente L, Mariscal N, Alcaraz R, Aguado L, Rivadeneyra-Posadas J, Sanz-Solas A, Saiz-Rodriguez M (2023) Pharmacogenetics in the treatment of Huntington\u2019s disease: review and future perspectives. J Pers Med 13","DOI":"10.3390\/jpm13030385"},{"key":"4444_CR86","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Gonz\u00e1lez X, Cubo E, Sim\u00f3n-Vicente L, Mariscal N, Alcaraz R, Aguado L, Rivadeneyra-Posadas J, Sanz-Solas A, Saiz-Rodr\u00edguez M (2023) Pharmacogenetics in the treatment of Huntington\u2019s disease: review and future perspectives. J Pers Med 13","DOI":"10.3390\/jpm13030385"},{"key":"4444_CR87","doi-asserted-by":"publisher","first-page":"31652","DOI":"10.1038\/srep31652","volume":"6","author":"M Garcia-Miralles","year":"2016","unstructured":"Garcia-Miralles M, Hong X, Tan LJ, Caron NS, Huang Y, To XV, Lin RY, Franciosi S, Papapetropoulos S, Hayardeny L, Hayden MR, Chuang KH, Pouladi MA (2016) Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease. Sci Rep 6:31652","journal-title":"Sci Rep"},{"key":"4444_CR88","doi-asserted-by":"publisher","first-page":"4464","DOI":"10.1007\/s12035-018-1393-1","volume":"56","author":"M Garcia-Miralles","year":"2019","unstructured":"Garcia-Miralles M, Yusof N, Tan JY, Radulescu CI, Sidik H, Tan LJ, Belinson H, Zach N, Hayden MR, Pouladi MA (2019) Laquinimod treatment improves myelination deficits at the transcriptional and ultrastructural levels in the YAC128 mouse model of Huntington disease. Mol Neurobiol 56:4464\u20134478","journal-title":"Mol Neurobiol"},{"key":"4444_CR89","doi-asserted-by":"crossref","unstructured":"G\u00e1rdi\u00e1n G, V\u00e9csei L (2004) Huntington\u2019s disease: pathomechanism and therapeutic perspectives.\u00a0J Neural Transm\u00a0111:1485\u20131494","DOI":"10.1007\/s00702-004-0201-4"},{"key":"4444_CR90","first-page":"369","volume":"105","author":"K Gharami","year":"2008","unstructured":"Gharami K, Xie Y, An JJ, Tonegawa S (2008) Xu BJJon. Brain-Derived Neurotrophic Factor over-Expression in the Forebrain Ameliorates Huntington\u2019s Disease Phenotypes in Mice 105:369\u2013379","journal-title":"Brain-Derived Neurotrophic Factor over-Expression in the Forebrain Ameliorates Huntington\u2019s Disease Phenotypes in Mice"},{"key":"4444_CR91","unstructured":"Ghosh R, Tabrizi S (2015) Clinical aspects of Huntington\u2019s disease. Behav Neurobial Huntington\u2019s Dis Parkinson\u2019s Dis. pp. 3\u201331"},{"key":"4444_CR92","doi-asserted-by":"crossref","unstructured":"Giamp\u00e0 C, Laurenti D, Anzilotti S, Bernardi G, Menniti FS, Fusco FRJPo (2010) Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6\/2 mouse model of Huntington\u2019s disease. 5: e13417","DOI":"10.1371\/journal.pone.0013417"},{"key":"4444_CR93","doi-asserted-by":"crossref","unstructured":"Giamp\u00e0 C, Middei S, Patassini S, Borreca A, Marullo F, Laurenti D, Bernardi G, Ammassari\u2010Teule M, Fusco FRJEJoN (2009a) Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6\/2 mouse model of Huntington\u2019s disease. 29: 902\u2013910","DOI":"10.1111\/j.1460-9568.2009.06649.x"},{"key":"4444_CR94","doi-asserted-by":"crossref","unstructured":"Giamp\u00e0 C, Patassini S, Borreca A, Laurenti D, Marullo F, Bernardi G, Menniti FS, Fusco FRJNod (2009b) Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington\u2019s disease. 34: 450\u2013456","DOI":"10.1016\/j.nbd.2009.02.014"},{"key":"4444_CR95","doi-asserted-by":"crossref","unstructured":"G\u00f3mez CD, Buijs RM, Sitges MJJon (2014) The anti\u2010seizure drugs vinpocetine and carbamazepine, but not valproic acid, reduce inflammatory IL\u20101\u03b2 and TNF\u2010\u03b1 expression in rat hippocampus. 130: 770\u2013779","DOI":"10.1111\/jnc.12784"},{"key":"4444_CR96","doi-asserted-by":"publisher","first-page":"107963","DOI":"10.1016\/j.pharmthera.2021.107963","volume":"230","author":"H Gong","year":"2022","unstructured":"Gong H, Bandura J, Wang G-L, Feng Z-P, Sun H-S (2022) Xyloketal B: a marine compound with medicinal potential. Pharmacol Ther 230:107963","journal-title":"Pharmacol Ther"},{"key":"4444_CR97","doi-asserted-by":"crossref","unstructured":"Gonzalez-Moragas L, Roig A, Laromaine A (2015) C. elegans as a tool for in vivo nanoparticle assessment.","DOI":"10.1016\/j.cis.2015.02.001"},{"key":"4444_CR98","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.neuroscience.2012.07.060","volume":"227","author":"K Gopinath","year":"2012","unstructured":"Gopinath K, Sudhandiran G (2012) Naringin modulates oxidative stress and inflammation in 3-nitropropionic acid-induced neurodegeneration through the activation of nuclear factor-erythroid 2-related factor-2 signalling pathway. Neuroscience 227:134\u2013143","journal-title":"Neuroscience"},{"key":"4444_CR99","doi-asserted-by":"crossref","unstructured":"Grachev ID, Meyer PM, Becker GA, Bronzel M, Marsteller D, Pastino G, Voges O, Rabinovich L, Knebel H, Zientek FJEjonm, imaging m (2021) Sigma-1 and dopamine D2\/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [18 F] fluspidine and [18 F] fallypride PET study. 48: 1103\u20131115","DOI":"10.1007\/s00259-020-05030-3"},{"key":"4444_CR100","first-page":"1197","volume":"135","author":"R Grondin","year":"2012","unstructured":"Grondin R, Kaytor MD, Ai Y, Nelson PT, Thakker DR, Heisel J, Weatherspoon MR, Blum JL, Burright EN, Zhang ZJB (2012) Six-Month Partial Suppression of Huntingtin is Well Tolerated in the Adult Rhesus Striatum 135:1197\u20131209","journal-title":"Six-Month Partial Suppression of Huntingtin is Well Tolerated in the Adult Rhesus Striatum"},{"key":"4444_CR101","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.bbi.2023.12.023","volume":"116","author":"C Gubert","year":"2024","unstructured":"Gubert C, Kong G, Costello C, Adams C, Masson B, Qin W, Choo J, Narayana V, Rogers G, Renoir T, Furness J, Hannan A (2024) Dietary fibre confers therapeutic effects in a preclinical model of Huntington\u2019s disease. BRAIN BEHAVIOR AND IMMUNITY 116:404\u2013418","journal-title":"BRAIN BEHAVIOR AND IMMUNITY"},{"key":"4444_CR102","doi-asserted-by":"crossref","unstructured":"Gunn S, Dale M, Ovaska-Stafford N, Maltby J (2023) Mental health symptoms among those affected by Huntington\u2019s disease: a cross-sectional study. Brain Behav 13","DOI":"10.1002\/brb3.2954"},{"key":"4444_CR103","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/nature25502","volume":"555","author":"Q Guo","year":"2018","unstructured":"Guo Q, Huang B, Cheng J, Seefelder M, Engler T, Pfeifer G, Oeckl P, Otto M, Moser F, Maurer M (2018) The cryo-electron microscopy structure of huntingtin. Nature 555:117\u2013120","journal-title":"Nature"},{"key":"4444_CR104","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.sajb.2022.10.006","volume":"151","author":"M Gupta","year":"2022","unstructured":"Gupta M, Singh N, Singh B, Alam P (2022) Role of natural products in alleviation of Huntington\u2019s disease: an overview. S Afr J Bot 151:263\u2013276","journal-title":"S Afr J Bot"},{"key":"4444_CR105","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1080\/10401230490487007","volume":"16","author":"S Gupta","year":"2004","unstructured":"Gupta S, Masand P (2004) Aripiprazole: review of its pharmacology and therapeutic use in psychiatric disorders. Annals of Clinical Psychiatry\u202f: Official Journal of the American Academy of Clinical Psychiatrists 16:155\u2013166","journal-title":"Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists"},{"key":"4444_CR106","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1080\/00207454.2020.1821677","volume":"132","author":"M Haider","year":"2022","unstructured":"Haider M, Salman M, Kaushik P, Bharadwaj N, Aggarwal NB, Tabassum H, Parvez S (2022) Chrysin ameliorates 3 nitropropinoic acid induced neurotoxicity targeting behavioural, biochemical and histological alterations. Int J Neurosci 132:450\u2013458","journal-title":"Int J Neurosci"},{"key":"4444_CR107","doi-asserted-by":"publisher","first-page":"12","DOI":"10.5582\/irdr.2023.01111","volume":"13","author":"D He","year":"2024","unstructured":"He D, Wang R, Xu Z, Wang J, Song P, Wang H, Su J (2024) The use of artificial intelligence in the treatment of rare diseases: a scoping review. Intractable Rare Dis Res 13:12\u201322","journal-title":"Intractable Rare Dis Res"},{"key":"4444_CR108","doi-asserted-by":"publisher","first-page":"28420","DOI":"10.1038\/srep28420","volume":"6","author":"SM Heman-Ackah","year":"2016","unstructured":"Heman-Ackah SM, Bassett AR, Wood MJ (2016) Precision modulation of neurodegenerative disease-related gene expression in human iPSC-derived neurons. Sci Rep 6:28420","journal-title":"Sci Rep"},{"key":"4444_CR109","doi-asserted-by":"publisher","first-page":"4830","DOI":"10.1093\/hmg\/ddp455","volume":"18","author":"TL Henshall","year":"2009","unstructured":"Henshall TL, Tucker B, Lumsden AL, Nornes S, Lardelli MT, Richards RI (2009) Selective neuronal requirement for huntingtin in the developing zebrafish. Hum Mol Genet 18:4830\u20134842","journal-title":"Hum Mol Genet"},{"key":"4444_CR110","first-page":"1426","volume":"36","author":"D Hergert","year":"2021","unstructured":"Hergert D, Cimino C (2021) Predictors of Caregiver Burden in Huntington\u2019s Disease. Arch Clin Neuropsychol 36:1426\u20131437","journal-title":"Arch Clin Neuropsychol"},{"key":"4444_CR111","doi-asserted-by":"crossref","unstructured":"Herzog-Krzywoszanska R, Krzywoszanski L (2019) Sleep disorders in Huntington\u2019s disease. Front Psychiatry 10","DOI":"10.3389\/fpsyt.2019.00221"},{"key":"4444_CR112","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/cpt.147","volume":"98","author":"JK Hicks","year":"2015","unstructured":"Hicks JK, Bishop JR, Sangkuhl K, M\u00fcller DJ, Ji Y, Leckband SG, Leeder JS, Graham RL, Chiulli DL, A LL, Skaar TC, Scott SA, Stingl JC, Klein TE, Caudle KE, Gaedigk A (2015) Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin pharmacol ther 98:127\u2013134","journal-title":"Clin pharmacol ther"},{"key":"4444_CR113","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1056\/NEJMra1706910","volume":"381","author":"KA High","year":"2019","unstructured":"High KA, Roncarolo MG (2019) Gene therapy. N Engl J Med 381:455\u2013464","journal-title":"N Engl J Med"},{"key":"4444_CR114","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1007\/s00415-021-10511-y","volume":"268","author":"A Horta-Barba","year":"2021","unstructured":"Horta-Barba A, Pagonabarraga J, Mart\u00ednez-Horta S, Busteed L, Pascual-Sedano B, Ill\u00e1n-Gala I, Marin-Lahoz J, Aracil-Bola\u00f1os I, P\u00e9rez-P\u00e9rez J, Sampedro F, Bejr-Kasem H, Kulisevsky J (2021) Cognitive and behavioral profile of progressive supranuclear palsy and its phenotypes. J Neurol 268:3400\u20133408","journal-title":"J Neurol"},{"key":"4444_CR115","first-page":"201","volume":"9","author":"D Howland","year":"2020","unstructured":"Howland D, Ellederova Z, Aronin N, Fernau D, Gallagher J, Taylor A, Hennebold J, Weiss AR, Gray-Edwards H (2020) McBride JJJoHsd. Large Animal Models of Huntington\u2019s Disease: What We Have Learned and where We Need to Go next 9:201\u2013216","journal-title":"Large Animal Models of Huntington\u2019s Disease: What We Have Learned and where We Need to Go next"},{"key":"4444_CR116","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.3390\/brainsci12101389","volume":"12","author":"Z Irfan","year":"2022","unstructured":"Irfan Z, Khanam S, Karmakar V, Firdous SM, El Khier BSIA, Khan I, Rehman MU, Khan A (2022) Pathogenesis of Huntington\u2019s disease: an emphasis on molecular pathways and prevention by natural remedies. Brain Sci 12:1389","journal-title":"Brain Sci"},{"key":"4444_CR117","first-page":"135","volume":"498","author":"T Itoh","year":"2004","unstructured":"Itoh T, Tokumura M, Abe KJEjop (2004) Effects of rolipram, a phosphodiesterase 4 inhibitor, in combination with imipramine on depressive behavior. CRE-binding activity and BDNF level in learned helplessness rats. 498:135\u2013142","journal-title":"CRE-binding activity and BDNF level in learned helplessness rats."},{"key":"4444_CR118","doi-asserted-by":"crossref","unstructured":"Iyer RR,\u00a0Pluciennik A (2021) DNA mismatch repair and its role in Huntington\u2019s disease.\u00a0J Huntingtons Dis\u00a010:75\u201394","DOI":"10.3233\/JHD-200438"},{"key":"4444_CR119","first-page":"633","volume":"21","author":"GR Jackson","year":"1998","unstructured":"Jackson GR, Salecker I, Dong X, Yao X, Arnheim N, Faber PW, MacDonald ME, Zipursky SLJN (1998) Polyglutamine-Expanded Human Huntingtin Transgenes Induce Degeneration of Drosophila Photoreceptor Neurons 21:633\u2013642","journal-title":"Polyglutamine-Expanded Human Huntingtin Transgenes Induce Degeneration of Drosophila Photoreceptor Neurons"},{"key":"4444_CR120","doi-asserted-by":"crossref","unstructured":"Jaini A, Yomtoob J, Yeh C, Bega D (2020) Understanding HD psychosis: an analysis from the ENROLL-HD Database. Tremor and other hyperkinetic movements 10","DOI":"10.5334\/tohm.395"},{"key":"4444_CR121","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1586\/ern.11.149","volume":"11","author":"J Jankovic","year":"2011","unstructured":"Jankovic J, Clarence-Smith K (2011) Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev Neurother 11:1509\u20131523","journal-title":"Expert Rev Neurother"},{"key":"4444_CR122","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1007\/s00702-024-02750-w","volume":"131","author":"K Jellinger","year":"2024","unstructured":"Jellinger K (2024) The pathobiology of depression in Huntington\u2019s disease: an unresolved puzzle. J Neural Transm 131:1511\u20131522","journal-title":"J Neural Transm"},{"key":"4444_CR123","doi-asserted-by":"crossref","unstructured":"Jiang A, Handley R, Lehnert K, Snell R (2023) From pathogenesis to therapeutics: a review of 150 years of Huntington\u2019s disease research. Int J Mol Sci 24","DOI":"10.3390\/ijms241613021"},{"key":"4444_CR124","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1093\/hmg\/ddt098","volume":"22","author":"M Jiang","year":"2013","unstructured":"Jiang M, Peng Q, Liu X, Jin J, Hou Z, Zhang J, Mori S, Ross CA, Ye K, Duan W (2013) Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington\u2019s disease. Hum Mol Genet 22:2462\u20132470","journal-title":"Hum Mol Genet"},{"key":"4444_CR125","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1517\/21678707.2013.787358","volume":"1","author":"J Jimenez-Shahed","year":"2013","unstructured":"Jimenez-Shahed J, Jankovic J (2013) Tetrabenazine for treatment of chorea associated with Huntington\u2019s disease and other potential indications. Expert Opin Orphan Drugs 1:423\u2013436","journal-title":"Expert Opin Orphan Drugs"},{"key":"4444_CR126","first-page":"11","volume":"2","author":"A Joshi","year":"2017","unstructured":"Joshi A, Soni P, Malviya S, Kharia A (2017) Memory enhancing activity of Momordica charantia by scopolamine induced amnesia in rats. IJCAP 2:11\u201318","journal-title":"IJCAP"},{"key":"4444_CR127","doi-asserted-by":"publisher","first-page":"3992","DOI":"10.1007\/s12035-021-02397-8","volume":"58","author":"T Joshi","year":"2021","unstructured":"Joshi T, Kumar V, Kaznacheyeva EV, Jana NR (2021) Withaferin a induces heat shock response and ameliorates disease progression in a mouse model of Huntington\u2019s disease. Mol Neurobiol 58:3992\u20134006","journal-title":"Mol Neurobiol"},{"key":"4444_CR128","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0378-1119(98)00342-4","volume":"217","author":"CA Karlovich","year":"1998","unstructured":"Karlovich CA, John RM, Ramirez L, Stainier DY, Myers RM (1998) Characterization of the Huntington\u2019s disease (HD) gene homologue in the zebrafish Danio rerio. Gene 217:117\u2013125","journal-title":"Gene"},{"key":"4444_CR129","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1124\/dmd.111.042150","volume":"40","author":"Y Kato","year":"2012","unstructured":"Kato Y, Nakajima M, Oda S, Fukami T, Yokoi T (2012) Human UDP-glucuronosyltransferase isoforms involved in haloperidol glucuronidation and quantitative estimation of their contribution. Drug Metabolism and Disposition: the Biological Fate of Chemicals 40:240\u2013248","journal-title":"Drug Metabolism and Disposition: the Biological Fate of Chemicals"},{"key":"4444_CR130","doi-asserted-by":"crossref","unstructured":"Kaur K, Al-Khazaleh AK, Bhuyan DJ, Li F, Li CG (2024) A review of recent curcumin analogues and their antioxidant, anti-inflammatory, and anticancer activities. Antioxidants (Basel, Switzerland) 13","DOI":"10.20944\/preprints202403.1292.v1"},{"key":"4444_CR131","doi-asserted-by":"publisher","first-page":"E6145","DOI":"10.1073\/pnas.1607843113","volume":"113","author":"J Kaye","year":"2016","unstructured":"Kaye J, Piryatinsky V, Birnberg T, Hingaly T, Raymond E, Kashi R, Amit-Romach E, Caballero IS, Towfic F, Ator MA, Rubinstein E, Laifenfeld D, Orbach A, Shinar D, Marantz Y, Grossman I, Knappertz V, Hayden MR, Laufer R (2016) Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor. Proc Natl Acad Sci USA 113:E6145-e6152","journal-title":"Proc Natl Acad Sci USA"},{"key":"4444_CR132","doi-asserted-by":"crossref","unstructured":"Keller CG, Shin Y, Monteys AM, Renaud N, Beibel M, Teider N, Peters T, Faller T, St-Cyr S, Knehr JJNc (2022) An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusion. 13: 1150","DOI":"10.1038\/s41467-022-28653-6"},{"key":"4444_CR133","doi-asserted-by":"crossref","unstructured":"Khan A, Jahan S, Alshahrani S, Alshehri BM, Sameer AS, Arafah A, Ahmad A, Rehman MU (2021) Phytotherapeutic agents for neurodegenerative disorders: a neuropharmacological review. Phytomedicine. Elsevier, pp. 581\u2013620","DOI":"10.1016\/B978-0-12-824109-7.00012-1"},{"key":"4444_CR134","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3390\/biomedicines8080284","volume":"8","author":"A Khan","year":"2020","unstructured":"Khan A, Jahan S, Imtiyaz Z, Alshahrani S, Antar Makeen H, Mohammed Alshehri B, Kumar A, Arafah A, Rehman MU (2020) Neuroprotection: targeting multiple pathways by naturally occurring phytochemicals. Biomedicines 8:284","journal-title":"Biomedicines"},{"key":"4444_CR135","doi-asserted-by":"crossref","unstructured":"Kim A, Lalonde K, Truesdell A, Gomes Welter P, Brocardo PS, Rosenstock TR, Gil-Mohapel J (2021) New avenues for the treatment of Huntington\u2019s disease. Int J Mol Sci 22","DOI":"10.3390\/ijms22168363"},{"key":"4444_CR136","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/d41573-021-00088-6","volume":"20","author":"K Kingwell","year":"2021","unstructured":"Kingwell K (2021) Double setback for ASO trials in Huntington disease. Nat Rev Drug Discovery 20:412\u2013413","journal-title":"Nat Rev Drug Discovery"},{"key":"4444_CR137","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.neuroscience.2009.01.045","volume":"164","author":"S Kl\u00f6ppel","year":"2009","unstructured":"Kl\u00f6ppel S, Henley S, Hobbs N, Wolf R, Kassubek J, Tabrizi S, Frackowiak R (2009) Magnetic resonance imaging of Huntington\u2019s disease: preparing for clinical trials. Neuroscience 164:205\u2013219","journal-title":"Neuroscience"},{"key":"4444_CR138","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1146\/annurev-biochem-010909-095056","volume":"79","author":"A Klug","year":"2010","unstructured":"Klug A (2010) The discovery of zinc fingers and their applications in gene regulation and genome manipulation. Annu Rev Biochem 79:213\u2013231","journal-title":"Annu Rev Biochem"},{"key":"4444_CR139","first-page":"6024","volume":"26","author":"V Kmetzsch","year":"2022","unstructured":"Kmetzsch V, Becker E, Saracino D, Rinaldi D, Camuzat A, Le Ber I, Colliot O (2022) Biomedical P-DsgJIJo, Informatics H. Disease Progression Score Estimation from Multimodal Imaging and microRNA Data Using Supervised Variational Autoencoders 26:6024\u20136035","journal-title":"Disease Progression Score Estimation from Multimodal Imaging and microRNA Data Using Supervised Variational Autoencoders"},{"key":"4444_CR140","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s12325-020-01566-w","volume":"38","author":"D Koller","year":"2021","unstructured":"Koller D, Almenara S, Mej\u00eda G, Saiz-Rodr\u00edguez M, Zubiaur P, Rom\u00e1n M, Ochoa D, Navares-G\u00f3mez M, Santos-Molina E, Pintos-S\u00e1nchez E, Abad-Santos F (2021) Metabolic effects of aripiprazole and olanzapine multiple-dose treatment in a randomised crossover clinical trial in healthy volunteers: association with pharmacogenetics. Adv Ther 38:1035\u20131054","journal-title":"Adv Ther"},{"key":"4444_CR141","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.parkreldis.2014.03.017","volume":"20","author":"G Koutsis","year":"2014","unstructured":"Koutsis G, Karadima G, Kladi A, Panas M (2014) Late-onset Huntington\u2019s disease: diagnostic and prognostic considerations. Parkinsonism Relat Disord 20:726\u2013730","journal-title":"Parkinsonism Relat Disord"},{"key":"4444_CR142","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3233\/JHD-170256","volume":"6","author":"G Kringlen","year":"2017","unstructured":"Kringlen G, Kinsley L, Aufox S, Rouleau G, Bega D (2017) The impact of family history on the clinical features of Huntington\u2019s disease. JOURNAL OF HUNTINGTONS DISEASE 6:327\u2013335","journal-title":"JOURNAL OF HUNTINGTONS DISEASE"},{"key":"4444_CR143","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ejphar.2013.10.057","volume":"720","author":"A Kumar","year":"2013","unstructured":"Kumar A, Chaudhary T, Mishra J (2013) Minocycline modulates neuroprotective effect of hesperidin against quinolinic acid induced Huntington\u2019s disease like symptoms in rats: behavioral, biochemical, cellular and histological evidences. Eur J Pharmacol 720:16\u201328","journal-title":"Eur J Pharmacol"},{"key":"4444_CR144","doi-asserted-by":"publisher","first-page":"1","DOI":"10.9734\/BJPR\/2016\/28054","volume":"13","author":"A Kumar","year":"2016","unstructured":"Kumar A, Garg V (2016) A review on Huntington\u2019s disease. Br J Pharm Res 13:1\u201315","journal-title":"Br J Pharm Res"},{"key":"4444_CR145","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1016\/j.fct.2009.07.011","volume":"47","author":"P Kumar","year":"2009","unstructured":"Kumar P, Kumar A (2009) Effect of lycopene and epigallocatechin-3-gallate against 3-nitropropionic acid induced cognitive dysfunction and glutathione depletion in rat: a novel nitric oxide mechanism. Food Chem Toxicol 47:2522\u20132530","journal-title":"Food Chem Toxicol"},{"key":"4444_CR146","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.bbr.2009.08.028","volume":"206","author":"P Kumar","year":"2010","unstructured":"Kumar P, Kumar A (2010) Protective effect of hesperidin and naringin against 3-nitropropionic acid induced Huntington\u2019s like symptoms in rats: possible role of nitric oxide. Behav Brain Res 206:38\u201346","journal-title":"Behav Brain Res"},{"key":"4444_CR147","doi-asserted-by":"crossref","unstructured":"Kumar R, Claassen D, Mongan A, Hoehn B, Lin P, Cahir-Mcfarland E, Guo C, Volman V, Taylor L, Chandra PJN (2023a) A phase 2 open-label study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous ANX005 in patients with, or at risk of, manifest Huntington\u2019s disease (HD)(S32. 009). 100: 3366","DOI":"10.1212\/WNL.0000000000203217"},{"key":"4444_CR148","doi-asserted-by":"crossref","unstructured":"Kumar Y, Koul A, Singla R, Ijaz MFJJoai, computing h (2023b) Artificial intelligence in disease diagnosis: a systematic literature review, synthesizing framework and future research agenda. 14: 8459\u20138486","DOI":"10.1007\/s12652-021-03612-z"},{"key":"4444_CR149","doi-asserted-by":"crossref","unstructured":"Leavitt BR (2024) Current clinical trials of new therapeutic agents for Huntington\u2019s disease. Huntington\u2019s Disease. Elsevier, pp. 571\u2013589","DOI":"10.1016\/B978-0-323-95672-7.00015-7"},{"key":"4444_CR150","doi-asserted-by":"crossref","unstructured":"Lee H, Fenster R, Pineda S, Gibbs W, Mohammadi S, Davila-Velderrain J, Garcia F, Therrien M, Novis H, Gao F, Wilkinson H, Vogt T, Kellis M, LaVoie M, Heiman M (2020) Cell type-specific transcriptomics reveals that mutant huntingtin leads to mitochondrial RNA release and neuronal innate immune activation. Neuron 107: 891-+","DOI":"10.1016\/j.neuron.2020.06.021"},{"key":"4444_CR151","doi-asserted-by":"crossref","unstructured":"Lee J-M, Correia K, Loupe J, Kim K-H, Barker D, Hong EP, Chao MJ, Long JD, Lucente D, Vonsattel JPGJC (2019) CAG repeat not polyglutamine length determines timing of Huntington\u2019s disease onset. 178: 887\u2013900. e814","DOI":"10.1016\/j.cell.2019.06.036"},{"key":"4444_CR152","doi-asserted-by":"crossref","unstructured":"Lee J, Ramos E, Lee J et al (2012) CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology 78:690\u2013695","DOI":"10.1212\/WNL.0b013e318249f683"},{"key":"4444_CR153","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.cell.2015.07.003","volume":"162","author":"J Lee","year":"2015","unstructured":"Lee J, Wheeler V, Chao M, Vonsattel J, Pinto R, Lucente D, Abu-Elneel K, Ramos E, Mysore J, Gillis T, MacDonald M, Gusella J, Harold D, Stone T, Escott-Price V, Han J, Vedernikov A, Holmans P, Jones L, Kwak S, Mahmoudi M, Orth M, Landwehrmeyer G, Paulsen J, Dorsey E, Shoulson I, Myers R, Dis GMH (2015) Identification of genetic factors that modify clinical onset of Huntington\u2019s disease. Cell 162:516\u2013526","journal-title":"Cell"},{"key":"4444_CR154","doi-asserted-by":"crossref","unstructured":"Lefkowitz RJ (2004) Historical review: a brief history and personal retrospective of seven-transmembrane receptors.\u00a0Trends Pharmacol Sci 25(8):413\u2013422","DOI":"10.1016\/j.tips.2004.06.006"},{"key":"4444_CR155","doi-asserted-by":"crossref","unstructured":"Levy R, Czernecki V (2006) Apathy and the basal ganglia.\u00a0J Neurol 253:vii54\u2013vii61","DOI":"10.1007\/s00415-006-7012-5"},{"key":"4444_CR156","doi-asserted-by":"publisher","first-page":"178","DOI":"10.5483\/BMBRep.2022-0157","volume":"56","author":"E Li","year":"2023","unstructured":"Li E, Choi J, Sim HR, Kim J, Jun JH, Kyung J, Ha N, Kim S, Ryu KH, Chung SS, Kim HS, Lee S, Seol W, Song J (2023) A novel HDAC6 inhibitor, CKD-504, is effective in treating preclinical models of Huntington\u2019s disease. BMB Rep 56:178\u2013183","journal-title":"BMB Rep"},{"key":"4444_CR157","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1142\/S0192415X1950040X","volume":"47","author":"J Li","year":"2019","unstructured":"Li J, Hao J (2019) Treatment of neurodegenerative diseases with bioactive components of Tripterygium wilfordii. Am J Chin Med 47:769\u2013785","journal-title":"Am J Chin Med"},{"key":"4444_CR158","doi-asserted-by":"publisher","first-page":"14947","DOI":"10.1038\/s41598-018-32960-8","volume":"8","author":"M-Y Li","year":"2018","unstructured":"Li M-Y, Chang C-T, Han Y-T, Liao C-P, Yu J-Y, Wang T-W (2018) Ginkgolide B promotes neuronal differentiation through the Wnt\/\u03b2-catenin pathway in neural stem cells of the postnatal mammalian subventricular zone. Sci Rep 8:14947","journal-title":"Sci Rep"},{"key":"4444_CR159","doi-asserted-by":"crossref","unstructured":"Li X, Tong H, Xu S, Zhou G, Yang T, Yin S, Yang S, Li X, Li S (2024) Neuroinflammatory proteins in Huntington\u2019s disease: insights into mechanisms, diagnosis, and therapeutic implications. Int J Mol Sci 25","DOI":"10.3390\/ijms252111787"},{"key":"4444_CR160","first-page":"481","volume":"541","author":"SA Liddelow","year":"2017","unstructured":"Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, Bennett ML, M\u00fcnch AE, Chung W-S, Peterson TCJN (2017) Neurotoxic Reactive Astrocytes are Induced by Activated Microglia 541:481\u2013487","journal-title":"Neurotoxic Reactive Astrocytes are Induced by Activated Microglia"},{"key":"4444_CR161","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/hmg\/10.2.137","volume":"10","author":"C-H Lin","year":"2001","unstructured":"Lin C-H, Tallaksen-Greene S, Chien W-M, Cearley JA, Jackson WS, Crouse AB, Ren S, Li X-J, Albin RL, Detloff PJ (2001) Neurological abnormalities in a knock-in mouse model of Huntington\u2019s disease. Hum Mol Genet 10:137\u2013144","journal-title":"Hum Mol Genet"},{"key":"4444_CR162","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.bbrc.2016.09.065","volume":"483","author":"G Liot","year":"2017","unstructured":"Liot G, Valette J, P\u00e9pin J, Flament J, Brouillet E (2017) Energy defects in Huntington\u2019s disease: Why \u201cin vivo\u201d evidence matters. Biochem Biophys Res Commun 483:1084\u20131095","journal-title":"Biochem Biophys Res Commun"},{"key":"4444_CR163","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/nn.3080","volume":"15","author":"V Lo Sardo","year":"2012","unstructured":"Lo Sardo V, Zuccato C, Gaudenzi G, Vitali B, Ramos C, Tartari M, Myre MA, Walker JA, Pistocchi A, Conti L, Valenza M, Drung B, Schmidt B, Gusella J, Zeitlin S, Cotelli F, Cattaneo E (2012) An evolutionary recent neuroepithelial cell adhesion function of huntingtin implicates ADAM10-Ncadherin. Nat Neurosci 15:713\u2013721","journal-title":"Nat Neurosci"},{"key":"4444_CR164","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1177\/1039856218766120","volume":"26","author":"SM Loi","year":"2018","unstructured":"Loi SM, Walterfang M, Velakoulis D, Looi JC (2018) Huntington\u2019s disease: managing neuropsychiatric symptoms in Huntington\u2019s disease. Australasian Psychiatry\u202f: Bulletin of Royal Australian and New Zealand College of Psychiatrists 26:376\u2013380","journal-title":"Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists"},{"key":"4444_CR165","doi-asserted-by":"crossref","unstructured":"Long E, Lin H, Liu Z, Wu X, Wang L, Jiang J, An Y, Lin Z, Li X, Chen JJNbe (2017) An artificial intelligence platform for the multihospital collaborative management of congenital cataracts. 1: 0024","DOI":"10.1038\/s41551-016-0024"},{"key":"4444_CR166","doi-asserted-by":"crossref","unstructured":"Lozada P, Perez J, Salinas R, Morales B, Mes\u00edas J, R\u00edos C, Rodas J, Leon-Rojas J (2024) Early diagnosis of Huntington disease: insights from magnetic resonance spectroscopy-a systematic review. J Clin Med 13","DOI":"10.3390\/jcm13216390"},{"key":"4444_CR167","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1021\/acschemneuro.0c00824","volume":"12","author":"PT Lum","year":"2021","unstructured":"Lum PT, Sekar M, Gan SH, Bonam SR, Shaikh MF (2021) Protective effect of natural products against Huntington\u2019s disease: an overview of scientific evidence and understanding their mechanism of action. ACS Chem Neurosci 12:391\u2013418","journal-title":"ACS Chem Neurosci"},{"key":"4444_CR168","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1093\/hmg\/ddm138","volume":"16","author":"AL Lumsden","year":"2007","unstructured":"Lumsden AL, Henshall TL, Dayan S, Lardelli MT, Richards RI (2007) Huntingtin-deficient zebrafish exhibit defects in iron utilization and development. Hum Mol Genet 16:1905\u20131920","journal-title":"Hum Mol Genet"},{"key":"4444_CR169","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","author":"M Macdonald","year":"1993","unstructured":"Macdonald M, Ambrose C, Duyao M, Myers R, Lin C, Srinidhi L, Barnes G, Taylor S, James M, Groot N, Macfarlane H, Jenkins B, Anderson M, Wexler N, Gusella J, Bates G, Baxendale S, Hummerich H, Kirby S, North M, Youngman S, Mott R, Zehetner G, SEdlacek Z, Poustka A, Frischauf A, Lehrach H, Buckler A, Church D, Doucettestamm L, Odonovan M, Ribaramirez L, Shah M, Stanton V, Strobel S, Draths K, Wales J, Dervan P, Housman D, Altherr M, SHIANG R, Thompson L, Fielder T, Wasmuth J, Tagle D, Valdes J, Elmer L, Allard M, Castilla L, Swaroop M, Blanchard K, Collins F, Snell R, Holloway T, Gillespie K, Datson N, Shaw D, Harper P (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell 72:971\u2013983","journal-title":"Cell"},{"key":"4444_CR170","doi-asserted-by":"crossref","unstructured":"Maity S, Komal P, Kumar V, Saxena A, Tungekar A, Chandrasekar V (2022) Impact of ER stress and ER-mitochondrial crosstalk in Huntington\u2019s disease. Int J Mol Sci 23","DOI":"10.3390\/ijms23020780"},{"key":"4444_CR171","first-page":"1382","volume":"70","author":"K Marder","year":"2013","unstructured":"Marder K, Gu Y, Eberly S, Tanner C, Scarmeas N, Oakes D, Shoulson I, Invest HSGP (2013) Relationship of Mediterranean diet and caloric intake to phenoconversion in Huntington disease. JAMA Neurol 70:1382\u20131388","journal-title":"JAMA Neurol"},{"key":"4444_CR172","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.parkreldis.2016.02.008","volume":"25","author":"S Martinez-Horta","year":"2016","unstructured":"Martinez-Horta S, Perez-Perez J, van Duijn E, Fernandez-Bobadilla R, Carceller M, Pagonabarraga J, Pascual-Sedano B, Campolongo A, Ruiz-Idiago J, Sampedro F, Landwehrmeyer G, Kulisevsky J, Network EHsD (2016) Neuropsychiatric symptoms are very common in premanifest and early stage Huntington\u2019s Disease. Parkinsonism Relat Disord 25:58\u201364","journal-title":"Parkinsonism Relat Disord"},{"key":"4444_CR173","unstructured":"McBride J, Ramaswamy S, Kordower J (2004) GDNF gene therapy in the N171\u201382Q transgenic mouse model of Huntington\u2019s disease. experimental neurology. Academic Press inc elsevier science 525 B ST, STE 1900, San Diego, CA 92101\u00a0\u2026, pp. 214\u2013214"},{"key":"4444_CR174","first-page":"5868","volume":"105","author":"JL McBride","year":"2008","unstructured":"McBride JL, Boudreau RL, Harper SQ, Staber PD, Monteys AM, Martins I, Gilmore BL, Burstein H, Peluso RW (2008) Polisky BJPotNAoS. Artificial miRNAs Mitigate shRNA-Mediated Toxicity in the Brain: Implications for the Therapeutic Development of RNAi 105:5868\u20135873","journal-title":"Artificial miRNAs Mitigate shRNA-Mediated Toxicity in the Brain: Implications for the Therapeutic Development of RNAi"},{"key":"4444_CR175","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/ene.13413","volume":"25","author":"P McColgan","year":"2018","unstructured":"McColgan P, Tabrizi S (2018) Huntington\u2019s disease: a clinical review. Eur J Neurol 25:24\u201334","journal-title":"Eur J Neurol"},{"key":"4444_CR176","doi-asserted-by":"crossref","unstructured":"McCusker E, Loy C (2014) The many facets of unawareness in Huntington disease. Tremor and other Hyperkinetic Movements 4","DOI":"10.5334\/tohm.231"},{"key":"4444_CR177","first-page":"371","volume":"9","author":"A McGarry","year":"2020","unstructured":"McGarry A, Leinonen M, Kieburtz K, Geva M, Olanow CW (2020) Hayden MJJoHsd. Effects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD Study 9:371\u2013380","journal-title":"Effects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD Study"},{"key":"4444_CR178","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3233\/JHD-210482","volume":"10","author":"ER Mears","year":"2021","unstructured":"Mears ER, Handley RR, Grant MJ, Reid SJ, Day BT, Rudiger SR, McLaughlan CJ, Verma PJ, Bawden SC, Patassini S, Unwin RD, Cooper GJS, Gusella JF, MacDonald ME, Brauning R, Maclean P, Pearson JF, Waldvogel HJ, Faull RLM, Snell RG (2021) A multi-omic Huntington\u2019s disease transgenic sheep-model database for investigating disease pathogenesis. J Huntingtons Dis 10:423\u2013434","journal-title":"J Huntingtons Dis"},{"key":"4444_CR179","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1002\/mds.29228","volume":"37","author":"A Medina","year":"2022","unstructured":"Medina A, Mahjoub Y, Shaver L, Pringsheim T (2022) Prevalence and incidence of Huntington\u2019s disease: an updated systematic review and meta-analysis. Mov Disord 37:2327\u20132335","journal-title":"Mov Disord"},{"key":"4444_CR180","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1602\/neurorx.2.3.465","volume":"2","author":"LB Menalled","year":"2005","unstructured":"Menalled LB (2005) Knock-in mouse models of Huntington\u2019s disease. NeuroRx 2:465\u2013470","journal-title":"NeuroRx"},{"key":"4444_CR181","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.neuro.2012.07.007","volume":"33","author":"ET Menze","year":"2012","unstructured":"Menze ET, Tadros MG, Abdel-Tawab AM, Khalifa AE (2012) Potential neuroprotective effects of hesperidin on 3-nitropropionic acid-induced neurotoxicity in rats. Neurotoxicology 33:1265\u20131275","journal-title":"Neurotoxicology"},{"key":"4444_CR182","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1002\/mds.26675","volume":"31","author":"T Mestre","year":"2016","unstructured":"Mestre T, van Duijn E, Davis A, Bachoud-L\u00e9vi A, Busse M, Anderson K, Ferreira J, Mahlknecht P, Tumas V, Sampaio C, Goetz C, Cubo E, Stebbins G, Martinez-Martin P, Dev MCRS (2016) Rating scales for behavioral symptoms in Huntington\u2019s disease: critique and recommendations. Mov Disord 31:1466\u20131478","journal-title":"Mov Disord"},{"key":"4444_CR183","doi-asserted-by":"publisher","first-page":"e27746","DOI":"10.1371\/journal.pone.0027746","volume":"6","author":"M Mielcarek","year":"2011","unstructured":"Mielcarek M, Benn CL, Franklin SA, Smith DL, Woodman B, Marks PA, Bates GP (2011) SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6\/2 mouse model of Huntington\u2019s disease. PLoS ONE 6:e27746","journal-title":"PLoS ONE"},{"key":"4444_CR184","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.ymthe.2018.02.002","volume":"26","author":"J Miniarikova","year":"2018","unstructured":"Miniarikova J, Evers MM, Konstantinova P (2018) Translation of MicroRNA-based Huntingtin-lowering therapies from preclinical studies to the clinic. Molecular Therapy\u202f: the Journal of the American Society of Gene Therapy 26:947\u2013962","journal-title":"Molecular Therapy : the Journal of the American Society of Gene Therapy"},{"key":"4444_CR185","doi-asserted-by":"publisher","first-page":"109771","DOI":"10.1016\/j.intimp.2023.109771","volume":"116","author":"OE Mohamed","year":"2023","unstructured":"Mohamed OE, Abdallah DM, Fayez AM, Mohamed RA, El-Abhar HS (2023) Morin post-treatment surpassed calpeptin in ameliorating 3-NP-induced cortical neurotoxicity via modulation of glutamate\/calpain axis, Kidins220, and BDNF\/TrkB\/AKT\/CREB trajectory. Int Immunopharmacol 116:109771","journal-title":"Int Immunopharmacol"},{"key":"4444_CR186","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ymthe.2016.11.010","volume":"25","author":"AM Monteys","year":"2017","unstructured":"Monteys AM, Ebanks SA, Keiser MS, Davidson BL (2017) CRISPR\/Cas9 editing of the mutant huntingtin allele in vitro and in vivo. Molecular Therapy\u202f: the Journal of the American Society of Gene Therapy 25:12\u201323","journal-title":"Molecular Therapy : the Journal of the American Society of Gene Therapy"},{"key":"4444_CR187","doi-asserted-by":"publisher","first-page":"e15752","DOI":"10.1371\/journal.pone.0015752","volume":"6","author":"AJ Morton","year":"2011","unstructured":"Morton AJ, Avanzo L (2011) Executive decision-making in the domestic sheep. PLoS ONE 6:e15752","journal-title":"PLoS ONE"},{"key":"4444_CR188","first-page":"3375","volume":"23","author":"AJ Morton","year":"2014","unstructured":"Morton AJ, Rudiger SR, Wood NI, Sawiak SJ, Brown GC, Mclaughlan CJ, Kuchel TR, Snell RG, Faull RL (2014) Bawden CSJHmg. Early and Progressive Circadian Abnormalities in Huntington\u2019s Disease Sheep are Unmasked by Social Environment 23:3375\u20133383","journal-title":"Early and Progressive Circadian Abnormalities in Huntington\u2019s Disease Sheep are Unmasked by Social Environment"},{"key":"4444_CR189","doi-asserted-by":"crossref","unstructured":"Morton AJ (2023) Sleep and circadian rhythm dysfunction in animal models of Huntington\u2019s disease.\u00a0J Huntingtons Dis 12:133\u2013148","DOI":"10.3233\/JHD-230574"},{"key":"4444_CR190","first-page":"701","volume":"16","author":"DJH Moss","year":"2017","unstructured":"Moss DJH, Pardi\u00f1as AF, Langbehn D, Lo K, Leavitt BR, Roos R, Durr A, Mead S, Coleman A (2017) Santos RDJTLN. Identification of Genetic Variants Associated with Huntington\u2019s Disease Progression: a Genome-Wide Association Study 16:701\u2013711","journal-title":"Identification of Genetic Variants Associated with Huntington\u2019s Disease Progression: a Genome-Wide Association Study"},{"key":"4444_CR191","first-page":"871","volume":"95","author":"A M\u00fchlb\u00e4ck","year":"2024","unstructured":"M\u00fchlb\u00e4ck A, Hoffmann R, Pozzi N, Marziniak M, Brieger P, Dose M, Priller J (2024) Psychiatric Symptoms of Huntington\u2019s Disease NERVENARZT 95:871\u2013884","journal-title":"Psychiatric Symptoms of Huntington\u2019s Disease NERVENARZT"},{"key":"4444_CR192","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s13311-021-01022-9","volume":"18","author":"L Naia","year":"2021","unstructured":"Naia L, Ly P, Mota SI, Lopes C, Maranga C, Coelho P, Gershoni-Emek N, Ankarcrona M, Geva M, Hayden MR, Rego AC (2021) The Sigma-1 receptor mediates pridopidine rescue of mitochondrial function in Huntington disease models. Neurotherapeutics\u202f: the Journal of the American Society for Experimental NeuroTherapeutics 18:1017\u20131038","journal-title":"Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics"},{"key":"4444_CR193","doi-asserted-by":"crossref","unstructured":"Naik N, Hameed BZ, Shetty DK, Swain D, Shah M, Paul R, Aggarwal K, Ibrahim S, Patil V, Smriti KJFis (2022) Legal and ethical consideration in artificial intelligence in healthcare: who takes responsibility? 9: 862322","DOI":"10.3389\/fsurg.2022.862322"},{"key":"4444_CR194","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/mds.28391","volume":"36","author":"V Niemela","year":"2021","unstructured":"Niemela V, Landtblom A, Nyholm D, Kneider M, Constantinescu R, Paucar M, Svenningsson P, Abujrais S, Burman J, Shevchenko G, Bergquist J, Sundblom J (2021) Proenkephalin decreases in cerebrospinal fluid with symptom progression of Huntington\u2019s disease. Mov Disord 36:481\u2013491","journal-title":"Mov Disord"},{"key":"4444_CR195","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/j.1601-5215.2011.00563.x","volume":"23","author":"S Nimmagadda","year":"2011","unstructured":"Nimmagadda S, Agrawal N, Worrall-Davies A, Markova I, Rickards H (2011) Determinants of irritability in Huntington\u2019s disease. ACTA NEUROPSYCHIATRICA 23:309\u2013314","journal-title":"ACTA NEUROPSYCHIATRICA"},{"key":"4444_CR196","doi-asserted-by":"crossref","unstructured":"Nittari G, Roy P, Martinelli I, Bellitto V, Tomassoni D, Traini E, Tayebati SK, Amenta F (2023) Rodent models of Huntington\u2019s disease: an overview. Biomedicines 11","DOI":"10.3390\/biomedicines11123331"},{"key":"4444_CR197","unstructured":"Nucifora FC Jr (2001) The cellular pathogenesis of Huntington\u2019s disease and related disorders. The Johns Hopkins University"},{"key":"4444_CR198","doi-asserted-by":"crossref","unstructured":"Numakawa T, Kajihara R (2024) An interaction between brain-derived neurotrophic factor and stress-related glucocorticoids in the pathophysiology of Alzheimer\u2019s disease. Int J Mol Sci 25(3):1596","DOI":"10.3390\/ijms25031596"},{"key":"4444_CR199","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.parkreldis.2021.08.011","volume":"91","author":"A Ogilvie","year":"2021","unstructured":"Ogilvie A, Nopoulos P, Schultz J (2021) Sleep disturbances by disease type and stage in Huntington\u2019s disease. Parkinsonism Relat Disord 91:13\u201318","journal-title":"Parkinsonism Relat Disord"},{"key":"4444_CR200","doi-asserted-by":"crossref","unstructured":"Ouary S, Bizat N, Altairac S, Menetrat H, Mittoux V, Conde F, Hantraye P, Brouillet EJN (2000) Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid in rats: implications for neuroprotection studies. 97: 521\u2013530","DOI":"10.1016\/S0306-4522(00)00020-8"},{"key":"4444_CR201","doi-asserted-by":"crossref","unstructured":"Palfi S, Leventhal L, Goetz CG, Hantraye P, Roitberg BZ, Sramek J, Emborg M, Kordower JHJMdojotMDS (2000) Delayed onset of progressive dystonia following subacute 3\u2010nitropropionic acid treatment in Cebus apella monkeys. 15: 524\u2013530","DOI":"10.1002\/1531-8257(200005)15:3<524::AID-MDS1016>3.0.CO;2-F"},{"key":"4444_CR202","doi-asserted-by":"crossref","unstructured":"Pardo Mu\u00f1oz M, Garc\u00eda-D\u00edaz Barriga G, Straccia M, Sanders P, Alberch i Vi\u00e9 J, Canals i Coll JM, Consortium Hi (2017) Developmental alterations in Huntington\u2019s disease neural cells and pharmacological rescue in cells and mice. Nat Neurosci 20(5):648\u2013660","DOI":"10.1038\/nn.4532"},{"key":"4444_CR203","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1136\/jnnp.71.3.310","volume":"71","author":"JS Paulsen","year":"2001","unstructured":"Paulsen JS, Ready RE, Hamilton JM, Mega MS, Cummings JL (2001) Neuropsychiatric aspects of Huntington\u2019s disease. J Neurol Neurosurg Psychiatry 71:310\u2013314","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"4444_CR204","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/mdc3.13459","volume":"9","author":"M Peball","year":"2022","unstructured":"Peball M, Heim B, Ellmerer P, Frank F, Busin N, Galffy M, Djamshidian A, Seppi K (2022) Hospital admissions of Huntington\u2019s disease patients in a Huntington\u2019s disease centre between 2011 and 2016: a retrospective analysis. Mov Disord Clin Pract 9:628\u2013636","journal-title":"Mov Disord Clin Pract"},{"key":"4444_CR205","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/hmg\/ddi004","volume":"14","author":"A Peters\u00e9n","year":"2005","unstructured":"Peters\u00e9n A, Gil J, Maat-Schieman ML, Bj\u00f6rkqvist M, Tanila H, Ara\u00fajo IM, Smith R, Popovic N, Wierup N, Norl\u00e9n P, Li JY, Roos RA, Sundler F, Mulder H, Brundin P (2005) Orexin loss in Huntington\u2019s disease. Hum Mol Genet 14:39\u201347","journal-title":"Hum Mol Genet"},{"key":"4444_CR206","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/BF03160062","volume":"12","author":"C Peyser","year":"1990","unstructured":"Peyser C, Folstein S (1990) Huntington\u2019s disease as a model for mood disorders - clues from neuropathology and neurochemistry. Mol Chem Neuropathol 12:99\u2013119","journal-title":"Mol Chem Neuropathol"},{"key":"4444_CR207","doi-asserted-by":"publisher","first-page":"7202","DOI":"10.1038\/s41598-019-43627-3","volume":"9","author":"J Pido-Lopez","year":"2019","unstructured":"Pido-Lopez J, Tanudjojo B, Farag S, Bondulich MK, Andre R, Tabrizi SJ, Bates GP (2019) Inhibition of tumour necrosis factor alpha in the R6\/2 mouse model of Huntington\u2019s disease by etanercept treatment. Sci Rep 9:7202","journal-title":"Sci Rep"},{"key":"4444_CR208","doi-asserted-by":"publisher","first-page":"4336","DOI":"10.1007\/s12035-023-03347-2","volume":"60","author":"A Pirone","year":"2023","unstructured":"Pirone A, Ciregia F, Lazzarini G, Miragliotta V, Ronci M, Zuccarini M, Zallocco L, Beghelli D, Mazzoni MR, Lucacchini A (2023) Proteomic profiling reveals specific molecular hallmarks of the pig claustrum. Mol Neurobiol 60:4336\u20134358","journal-title":"Mol Neurobiol"},{"key":"4444_CR209","doi-asserted-by":"crossref","unstructured":"Porro A, Mohiuddin M, Zurfluh C, Spegg V, Dai J, Iehl F, Ropars V, Collotta G, Fishwick KM, Mozaffari NL, Gu\u00e9rois R, Jiricny J, Altmeyer M, Charbonnier JB, Pearson CE, Sartori AA (2021) FAN1-MLH1 interaction affects repair of DNA interstrand cross-links and slipped-CAG\/CTG repeats. Sci adv 7","DOI":"10.1126\/sciadv.abf7906"},{"key":"4444_CR210","doi-asserted-by":"crossref","unstructured":"Puerta E, Hervias I, Barros-Mi\u00f1ones L, Jordan J, Ricobaraza A, Cuadrado-Tejedor M, Garc\u00eda-Osta A, Aguirre NJNod (2010) Sildenafil protects against 3-nitropropionic acid neurotoxicity through the modulation of calpain, CREB, and BDNF. 38: 237\u2013245","DOI":"10.1016\/j.nbd.2010.01.013"},{"key":"4444_CR211","doi-asserted-by":"crossref","unstructured":"Puerta E, Hervias I, Go\u00f1i\u2010Allo B, Lasheras B, Jordan J, Aguirre NJJon (2009) Phosphodiesterase 5 inhibitors prevent 3, 4\u2010methylenedioxymethamphetamine\u2010induced 5\u2010HT deficits in the rat. 108: 755\u2013766","DOI":"10.1111\/j.1471-4159.2008.05825.x"},{"key":"4444_CR212","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.neures.2021.08.003","volume":"174","author":"B Purushothaman","year":"2022","unstructured":"Purushothaman B, Sumathi T (2022) 5, 6, 7 trihydroxy flavone armoured neurodegeneration caused by quinolinic acid induced Huntington\u2019s like disease in rat striatum-reinstating the level of brain neurotrophins with special reference to cognitive-socio behaviour, biochemical and histopathological aspects. Neurosci Res 174:25\u201335","journal-title":"Neurosci Res"},{"key":"4444_CR213","doi-asserted-by":"crossref","unstructured":"Puzzo D, Staniszewski A, Deng SX, Privitera L, Leznik E, Liu S, Zhang H, Feng Y, Palmeri A, Landry DWJJoN (2009) Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-\u03b2 load in an Alzheimer\u2019s disease mouse model. 29: 8075\u20138086","DOI":"10.1523\/JNEUROSCI.0864-09.2009"},{"key":"4444_CR214","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3126\/ijasbt.v5i2.16952","volume":"5","author":"K Rai","year":"2017","unstructured":"Rai K, Gupta N, Dharamdasani L, Nair P, Bodhankar P (2017) Bacopa monnieri: a wonder drug changing fortune of people. International Journal of Applied Sciences and Biotechnology 5:127\u2013132","journal-title":"International Journal of Applied Sciences and Biotechnology"},{"key":"4444_CR215","doi-asserted-by":"crossref","unstructured":"Ramaswamy S, McBride JL,\u00a0Kordower JH (2007) Animal Models of Huntington\u2019s Disease.\u00a0ILAR J\u00a048:356\u2013373","DOI":"10.1093\/ilar.48.4.356"},{"key":"4444_CR216","doi-asserted-by":"crossref","unstructured":"Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang FJNp (2013) Genome engineering using the CRISPR-Cas9 system. 8: 2281\u20132308","DOI":"10.1038\/nprot.2013.143"},{"key":"4444_CR217","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40898-017-0004-7","volume":"2","author":"G Ratheesh","year":"2017","unstructured":"Ratheesh G, Tian L, Venugopal JR, Ezhilarasu H, Sadiq A, Fan T-P, Ramakrishna S (2017) Role of medicinal plants in neurodegenerative diseases. Biomanufacturing Reviews 2:1\u201316","journal-title":"Biomanufacturing Reviews"},{"key":"4444_CR218","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.neurol.2024.04.001","volume":"180","author":"L Rati\u00e9","year":"2024","unstructured":"Rati\u00e9 L, Humbert S (2024) A developmental component to Huntington\u2019s disease. REVUE NEUROLOGIQUE 180:357\u2013362","journal-title":"REVUE NEUROLOGIQUE"},{"key":"4444_CR219","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1159\/000443738","volume":"46","author":"M Rawlins","year":"2016","unstructured":"Rawlins M, Wexler N, Wexler A, Tabrizi S, Douglas I, Evans S, Smeeth L (2016) The Prevalence of Huntington\u2019s Disease Neuroepidemiology 46:144\u2013153","journal-title":"The Prevalence of Huntington\u2019s Disease NEUROEPIDEMIOLOGY"},{"key":"4444_CR220","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.psychres.2012.03.041","volume":"200","author":"N Reedeker","year":"2012","unstructured":"Reedeker N, Bouwens J, Giltay E, Le Mair S, Roos R, van der Mast R, van Duijn E (2012) Irritability in Huntington\u2019s Disease Psychiatry Res 200:813\u2013818","journal-title":"Irritability in Huntington\u2019s Disease PSYCHIATRY RESEARCH"},{"key":"4444_CR221","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S1474-4422(23)00454-4","volume":"23","author":"R Reilmann","year":"2024","unstructured":"Reilmann R, Anderson KE, Feigin A, Tabrizi SJ, Leavitt BR, Stout JC, Piccini P, Schubert R, Loupe P, Wickenberg A, Borowsky B, Rynkowski G, Volkinshtein R, Li T, Savola JM, Hayden M, Gordon MF (2024) Safety and efficacy of laquinimod for Huntington\u2019s disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Neurol 23:243\u2013255","journal-title":"Lancet Neurol"},{"key":"4444_CR222","doi-asserted-by":"crossref","unstructured":"Rieckher M, Tavernarakis N (2017) Caenorhabditis elegans microinjection. Bio Protoc 7","DOI":"10.21769\/BioProtoc.2565"},{"key":"4444_CR223","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/S0006-8993(00)03174-7","volume":"889","author":"E Rink","year":"2001","unstructured":"Rink E, Wullimann MF (2001) The teleostean (zebrafish) dopaminergic system ascending to the subpallium (striatum) is located in the basal diencephalon (posterior tuberculum). Brain Res 889:316\u2013330","journal-title":"Brain Res"},{"key":"4444_CR224","first-page":"274","volume":"124","author":"RC Roberts","year":"1993","unstructured":"Roberts RC, Ahn A, Swartz KJ, Beal MF (1993) DiFiglia MJEn. Intrastriatal Injections of Quinolinic Acid or Kainic Acid: Differential Patterns of Cell Survival and the Effects of Data Analysis on Outcome 124:274\u2013282","journal-title":"Intrastriatal Injections of Quinolinic Acid or Kainic Acid: Differential Patterns of Cell Survival and the Effects of Data Analysis on Outcome"},{"key":"4444_CR225","doi-asserted-by":"crossref","unstructured":"Roli OI, Adetunji CO, Mishra RR, Adetunji JB, Mishra P, Fatoki TH (2020) Rediscovering medicinal activity and food significance of shogaol (4, 6, 8, 10, and 12): comprehensive review. Innovations in Food Technology: Current Perspectives and Future Goals: 125\u2013145","DOI":"10.1007\/978-981-15-6121-4_9"},{"key":"4444_CR226","doi-asserted-by":"crossref","unstructured":"Roman-Naranjo P, Parra-Perez AM, Lopez-Escamez JAJJobi (2023) A systematic review on machine learning approaches in the diagnosis and prognosis of rare genetic diseases. 143: 104429","DOI":"10.1016\/j.jbi.2023.104429"},{"key":"4444_CR227","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/mdc3.12808","volume":"6","author":"C Ross","year":"2019","unstructured":"Ross C, Reilmann R, Cardoso F, McCusker E, Testa C, Stout J, Leavitt B, Pei T, Landwehrmeyer B, Martinez A, Levey J, Srajer T, Bang J, Tabrizi S (2019) Movement disorder society task force viewpoint: Huntington\u2019s disease diagnostic categories. MOVEMENT DISORDERS CLINICAL PRACTICE 6:541\u2013546","journal-title":"MOVEMENT DISORDERS CLINICAL PRACTICE"},{"key":"4444_CR228","doi-asserted-by":"crossref","unstructured":"Roussakis AA, Gennaro M, Gordon MF, Reilmann R, Borowsky B, Rynkowski G, Lao-Kaim NP, Papoutsou Z, Savola JM, Hayden MR, Owen DR, Kalk N, Lingford-Hughes A, Gunn RN, Searle G, Tabrizi SJ, Piccini P (2023) A PET-CT study on neuroinflammation in Huntington\u2019s disease patients participating in a randomized trial with laquinimod. Brain communications 5: fcad084","DOI":"10.1093\/braincomms\/fcad084"},{"key":"4444_CR229","doi-asserted-by":"crossref","unstructured":"Roussos A, Kitopoulou K, Borbolis F, Palikaras K (2023) Caenorhabditis elegans as a model system to study human neurodegenerative disorders. Biomolecules 13","DOI":"10.3390\/biom13030478"},{"key":"4444_CR230","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41419-020-02897-w","volume":"11","author":"N Sada","year":"2020","unstructured":"Sada N, Fujita Y, Mizuta N, Ueno M, Furukawa T, Yamashita T (2020) Inhibition of HDAC increases BDNF expression and promotes neuronal rewiring and functional recovery after brain injury. Cell Death Dis 11:655","journal-title":"Cell Death Dis"},{"key":"4444_CR231","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1080\/1028415X.2021.1913319","volume":"25","author":"M Salman","year":"2022","unstructured":"Salman M, Sharma P, Alam MI, Tabassum H, Parvez S (2022) Naringenin mitigates behavioral alterations and provides neuroprotection against 3-nitropropinoic acid-induced Huntington\u2019s disease like symptoms in rats. Nutr Neurosci 25:1898\u20131908","journal-title":"Nutr Neurosci"},{"key":"4444_CR232","first-page":"624","volume":"58","author":"S Sammut","year":"2010","unstructured":"Sammut S, Threlfell S, West ARJN (2010) Nitric Oxide-Soluble Guanylyl Cyclase Signaling Regulates Corticostriatal Transmission and Short-Term Synaptic Plasticity of Striatal Projection Neurons Recorded in Vivo 58:624\u2013631","journal-title":"Nitric Oxide-Soluble Guanylyl Cyclase Signaling Regulates Corticostriatal Transmission and Short-Term Synaptic Plasticity of Striatal Projection Neurons Recorded in Vivo"},{"key":"4444_CR233","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/cpdd.882","volume":"10","author":"F Schneider","year":"2021","unstructured":"Schneider F, Stamler D, Bradbury M, Loupe PS, Hellriegel E, Cox DS, Savola JM, Gordon MF, Rabinovich-Guilatt L (2021) Pharmacokinetics of deutetrabenazine and tetrabenazine: dose proportionality and food effect. Clinical Pharmacology in Drug Development 10:647\u2013659","journal-title":"Clinical Pharmacology in Drug Development"},{"key":"4444_CR234","doi-asserted-by":"crossref","unstructured":"Setter S, Neumiller J, Dobbins E, Wood L, Clark J, DuVall C, Santiago A (2009) Treatment of chorea associated with Huntington\u2019s disease: focus on tetrabenazine. The Consultant Pharmacist\u00ae 24: 524\u2013537","DOI":"10.4140\/TCP.n.2009.524"},{"key":"4444_CR235","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s00210-021-02106-1","volume":"394","author":"P Sharma","year":"2021","unstructured":"Sharma P, Kumar M, Bansal N (2021) Ellagic acid prevents 3-nitropropionic acid induced symptoms of Huntington\u2019s disease. Naunyn Schmiedebergs Arch Pharmacol 394:1917\u20131928","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"4444_CR236","doi-asserted-by":"publisher","first-page":"158","DOI":"10.2174\/1573401318666220415084108","volume":"19","author":"S Sharma","year":"2023","unstructured":"Sharma S (2023) Role of Withania somnifera (Ashwagandha) in the treatment of neurological disorders. Curr Nutr Food Sci 19:158\u2013165","journal-title":"Curr Nutr Food Sci"},{"key":"4444_CR237","first-page":"305","volume":"150","author":"DA Shear","year":"1998","unstructured":"Shear DA, Dong J, Haik-Creguer KL, Bazzett TJ, Albin RL (1998) Dunbar GLJEn. Chronic Administration of Quinolinic Acid in the Rat Striatum Causes Spatial Learning Deficits in a Radial Arm Water Maze Task 150:305\u2013311","journal-title":"Chronic Administration of Quinolinic Acid in the Rat Striatum Causes Spatial Learning Deficits in a Radial Arm Water Maze Task"},{"key":"4444_CR238","first-page":"4566","volume":"25","author":"JW Shin","year":"2016","unstructured":"Shin JW, Kim KH, Chao MJ, Atwal RS, Gillis T, MacDonald ME, Gusella JF, Lee JM (2016) Permanent inactivation of Huntington\u2019s disease mutation by personalized allele-specific CRISPR\/Cas9. Hum Mol Genet 25:4566\u20134576","journal-title":"Hum Mol Genet"},{"key":"4444_CR239","doi-asserted-by":"publisher","first-page":"18712","DOI":"10.1523\/JNEUROSCI.1310-13.2013","volume":"33","author":"DA Simmons","year":"2013","unstructured":"Simmons DA, Belichenko NP, Yang T, Condon C, Monbureau M, Shamloo M, Jing D, Massa SM, Longo FM (2013) A small molecule TrkB ligand reduces motor impairment and neuropathology in R6\/2 and BACHD mouse models of Huntington\u2019s disease. The Journal of Neuroscience\u202f: the Official Journal of the Society for Neuroscience 33:18712\u201318727","journal-title":"The Journal of Neuroscience : the Official Journal of the Society for Neuroscience"},{"key":"4444_CR240","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.cortex.2019.06.012","volume":"120","author":"J Simpson","year":"2019","unstructured":"Simpson J, Dale M, Theed R, Gunn S, Zarotti N, Eccles F (2019) Validity of irritability in Huntington\u2019s disease: A scoping review. Cortex 120:353\u2013374","journal-title":"Cortex"},{"key":"4444_CR241","doi-asserted-by":"publisher","first-page":"105047","DOI":"10.1016\/j.jff.2022.105047","volume":"92","author":"P Singh","year":"2022","unstructured":"Singh P, Mishra G, Molla M, Yimer YS, Sisay W, Andargie Y, Ewunetie A (2022) Dietary and nutraceutical-based therapeutic approaches to combat the pathogenesis of Huntington\u2019s disease. Journal of Functional Foods 92:105047","journal-title":"Journal of Functional Foods"},{"key":"4444_CR242","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1093\/hmg\/ddg169","volume":"12","author":"EJ Slow","year":"2003","unstructured":"Slow EJ, van Raamsdonk J, Rogers D, Coleman SH, Graham RK, Deng Y, Oh R, Bissada N, Hossain SM, Yang Y-Z, Li X-J, Simpson EM, Gutekunst C-A, Leavitt BR, Hayden MR (2003) Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet 12:1555\u20131567","journal-title":"Hum Mol Genet"},{"key":"4444_CR243","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3389\/fncel.2019.00209","volume":"13","author":"AI Smith-Dijak","year":"2019","unstructured":"Smith-Dijak AI, Nassrallah WB, Zhang LYJ, Geva M, Hayden MR, Raymond LA (2019) Impairment and restoration of homeostatic plasticity in cultured cortical neurons from a mouse model of Huntington disease. Front Cell Neurosci 13:209","journal-title":"Front Cell Neurosci"},{"key":"4444_CR244","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/ana.10614","volume":"54","author":"DL Smith","year":"2003","unstructured":"Smith DL, Woodman B, Mahal A, Sathasivam K, Ghazi-Noori S, Lowden PA, Bates GP, Hockly E (2003) Minocycline and doxycycline are not beneficial in a model of Huntington\u2019s disease. Ann Neurol 54:186\u2013196","journal-title":"Ann Neurol"},{"key":"4444_CR245","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1037\/a0029218","volume":"26","author":"M Smith","year":"2012","unstructured":"Smith M, Mills J, Epping E, Westervelt H, Paulsen J, Investigators P-H (2012) Depressive symptom severity is related to poorer cognitive performance in prodromal Huntington disease. Neuropsychology 26:664\u2013669","journal-title":"Neuropsychology"},{"key":"4444_CR246","doi-asserted-by":"publisher","first-page":"3695","DOI":"10.1007\/s10072-021-05787-x","volume":"43","author":"P Soliveri","year":"2022","unstructured":"Soliveri P, Paridi D, Del Sorbo F, Tramacere I, Girotti F (2022) Negative symptoms in Huntington\u2019s disease. Neurol Sci 43:3695\u20133701","journal-title":"Neurol Sci"},{"key":"4444_CR247","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.2174\/1570159X19666210712151556","volume":"19","author":"AB Speers","year":"2021","unstructured":"Speers AB, Cabey KA, Soumyanath A, Wright KM (2021) Effects of Withania somnifera (Ashwagandha) on stress and the stress-related neuropsychiatric disorders anxiety, depression, and insomnia. Curr Neuropharmacol 19:1468","journal-title":"Curr Neuropharmacol"},{"key":"4444_CR248","doi-asserted-by":"crossref","unstructured":"Spick M, Hancox TP, Chowdhury NR, Middleton B, Skene DJ, Morton AJJJoHsd (2023) Metabolomic analysis of plasma in Huntington\u2019s disease transgenic sheep (Ovis aries) reveals progressive circadian rhythm dysregulation. 12: 31\u201342","DOI":"10.3233\/JHD-220552"},{"key":"4444_CR249","doi-asserted-by":"crossref","unstructured":"Stack EC, Kubilus JK, Smith K, Cormier K, Del Signore SJ, Guelin E, Ryu H, Hersch SM, Ferrante RJJJoCN (2005) Chronology of behavioral symptoms and neuropathological sequela in R6\/2 Huntington\u2019s disease transgenic mice. 490: 354\u2013370","DOI":"10.1002\/cne.20680"},{"key":"4444_CR250","doi-asserted-by":"crossref","unstructured":"Stoker T, Mason S, Greenland J, Holden S, Santini H, Barker R (2022) Huntington\u2019s disease: diagnosis and management. Pract Neurol 22: 32-+","DOI":"10.1136\/practneurol-2021-003074"},{"key":"4444_CR251","doi-asserted-by":"crossref","unstructured":"Stricker-Shaver J, Novati A, Yu-Taeger L, Nguyen H (2018) Genetic rodent models of Huntington disease. Polyglutamine Disorders: 29\u201357","DOI":"10.1007\/978-3-319-71779-1_2"},{"key":"4444_CR252","doi-asserted-by":"crossref","unstructured":"Sun Z, Del Mar N, Meade C, Goldowitz D, Reiner AJNod (2002) Differential changes in striatal projection neurons in R6\/2 transgenic mice for Huntington\u2019s disease. 11: 369\u2013385","DOI":"10.1006\/nbdi.2002.0554"},{"key":"4444_CR253","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/clpt.2011.34","volume":"89","author":"JJ Swen","year":"2011","unstructured":"Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, Rongen GA, van Schaik RH, Schalekamp T, Touw DJ, van der Weide J, Wilffert B, Deneer VH, Guchelaar HJ (2011) Pharmacogenetics: from bench to byte\u2013an update of guidelines. Clin Pharmacol Ther 89:662\u2013673","journal-title":"Clin Pharmacol Ther"},{"key":"4444_CR254","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41582-020-0389-4","volume":"16","author":"S Tabrizi","year":"2020","unstructured":"Tabrizi S, Flower M, Ross C, Wild E (2020) Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities. Nat Rev Neurol 16:529\u2013546","journal-title":"Nat Rev Neurol"},{"key":"4444_CR255","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S1474-4422(13)70088-7","volume":"12","author":"S Tabrizi","year":"2013","unstructured":"Tabrizi S, Scahill R, Owen G, Durr A, Leavitt B, Roos R, Borowsky B, Landwehrmeyer B, Frost C, Johnson H, Craufurd D, Reilmann R, Stout J, Langbehn D, Investigators T-H (2013) Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington\u2019s disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol 12:637\u2013649","journal-title":"Lancet Neurol"},{"key":"4444_CR256","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S1474-4422(22)00121-1","volume":"21","author":"SJ Tabrizi","year":"2022","unstructured":"Tabrizi SJ, Estevez-Fraga C, van Roon-Mom WMC, Flower MD, Scahill RI, Wild EJ, Munoz-Sanjuan I, Sampaio C, Rosser AE, Leavitt BR (2022) Potential disease-modifying therapies for Huntington\u2019s disease: lessons learned and future opportunities. Lancet Neurol 21:645\u2013658","journal-title":"Lancet Neurol"},{"key":"4444_CR257","doi-asserted-by":"crossref","unstructured":"Taghian T, Gallagher J, Batcho E, Pullan C, Kuchel T, Denney T, Perumal R, Moore S, Muirhead R, Herde PJJoHsd (2022) Brain alterations in aged OVT73 sheep model of Huntington\u2019s disease: an MRI based approach. 11: 391\u2013406","DOI":"10.3233\/JHD-220526"},{"key":"4444_CR258","unstructured":"Tamilanban T (2018) In vitro neuroprotective effect of charantin from Momordica charantia against neurotoxin and endoplasmic reticulum stress-induced cell death in SH-SY5Y cells. Int J Green Pharm (IJGP) 12"},{"key":"4444_CR259","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.biopha.2016.09.070","volume":"84","author":"S Thangarajan","year":"2016","unstructured":"Thangarajan S, Ramachandran S, Krishnamurthy P (2016) Chrysin exerts neuroprotective effects against 3-Nitropropionic acid induced behavioral despair\u2014mitochondrial dysfunction and striatal apoptosis via upregulating Bcl-2 gene and downregulating Bax\u2014Bad genes in male Wistar rats. Biomed Pharmacother 84:514\u2013525","journal-title":"Biomed Pharmacother"},{"key":"4444_CR260","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/jmp.12528","volume":"50","author":"CY Tian","year":"2021","unstructured":"Tian CY (2021) China is facing serious experimental monkey shortage during the COVID-19 lockdown. J Med Primatol 50:225\u2013227","journal-title":"J Med Primatol"},{"key":"4444_CR261","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/npp.2009.235","volume":"35","author":"AK Tiwari","year":"2010","unstructured":"Tiwari AK, Zai CC, Likhodi O, Lisker A, Singh D, Souza RP, Batra P, Zaidi SH, Chen S, Liu F, Puls I, Meltzer HY, Lieberman JA, Kennedy JL, M\u00fcller DJ (2010) A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia. Neuropsychopharmacology\u202f: Official Publication of the American College of Neuropsychopharmacology 35:1315\u20131324","journal-title":"Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology"},{"key":"4444_CR262","doi-asserted-by":"crossref","unstructured":"Tyagi N, Narayanan V, Singh NP, Prajapati A, Rauthan M, Tyagi MJB, Archives C (2024) Recent advances in phosphodiesterase inhibitors for the management of neurodegenerative disorders. 24","DOI":"10.51470\/bca.2024.24.1.433"},{"key":"4444_CR263","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/14737175.2016.1226134","volume":"17","author":"E Unti","year":"2017","unstructured":"Unti E, Mazzucchi S, Palermo G, Bonuccelli U, Ceravolo R (2017) Antipsychotic drugs in Huntington\u2019s disease. Expert Rev Neurother 17:227\u2013237","journal-title":"Expert Rev Neurother"},{"key":"4444_CR264","doi-asserted-by":"crossref","unstructured":"Vall\u00e8s A, Evers MM, Stam A, Sogorb-Gonzalez M, Brouwers C, Vendrell-Tornero C, Acar-Broekmans S, Paerels L, Klima J, Bohuslavova B, Pintauro R, Fodale V, Bresciani A, Liscak R, Urgosik D, Starek Z, Crha M, Blits B, Petry H, Ellederova Z, Motlik J, van Deventer S, Konstantinova P (2021) Widespread and sustained target engagement in Huntington\u2019s disease minipigs upon intrastriatal microRNA-based gene therapy. Science translational medicine 13","DOI":"10.1126\/scitranslmed.abb8920"},{"key":"4444_CR265","doi-asserted-by":"crossref","unstructured":"van Duijn E, Craufurd D, Hubers A, Giltay E, Bonelli R, Rickards H, Anderson K, van Walsem M, van der Mast R, Orth M, Landwehrmeyer G, Network EHsD (2014) Neuropsychiatric symptoms in a European Huntington\u2019s disease cohort (REGISTRY). J Neurol Neurosurg Psychiatry 85: 1411\u20131418","DOI":"10.1136\/jnnp-2013-307343"},{"key":"4444_CR266","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.4088\/JCP.v69n1116","volume":"69","author":"E van Duijn","year":"2008","unstructured":"van Duijn E, Kingma E, Timman R, Zitman F, Tibben A, Roos R, van der Mast R (2008) Cross-sectional study on prevalences of psychiatric disorders in mutation carriers of Huntington\u2019s disease compared with mutation-negative first-degree relatives. J Clin Psychiatry 69:1804\u20131810","journal-title":"J Clin Psychiatry"},{"key":"4444_CR267","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1176\/jnp.2010.22.3.287","volume":"22","author":"E van Duijn","year":"2010","unstructured":"van Duijn E, Reedeker N, Giltay E, Roos R, van der Mast R (2010) Correlates of apathy in Huntington\u2019s disease. J Neuropsychiatry Clin Neurosci 22:287\u2013294","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"4444_CR268","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1093\/hmg\/ddi407","volume":"14","author":"JM Van Raamsdonk","year":"2005","unstructured":"Van Raamsdonk JM, Murphy Z, Slow EJ, Leavitt BR, Hayden MR (2005) Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. Hum Mol Genet 14:3823\u20133835","journal-title":"Hum Mol Genet"},{"key":"4444_CR269","doi-asserted-by":"crossref","unstructured":"Vazey EM, Chen K, Hughes SM, Connor BJEn (2006) Transplanted adult neural progenitor cells survive, differentiate and reduce motor function impairment in a rodent model of Huntington\u2019s disease. 199: 384\u2013396","DOI":"10.1016\/j.expneurol.2006.01.034"},{"key":"4444_CR270","unstructured":"Vickers PJ (2013) Challenges and opportunities in the treatment of rare diseases.\u00a0Drug Discov World 14:9\u201316"},{"key":"4444_CR271","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.parkreldis.2008.10.002","volume":"15","author":"A Videnovic","year":"2009","unstructured":"Videnovic A, Leurgans S, Fan W, Jaglin J, Shannon K (2009) Daytime somnolence and nocturnal sleep disturbances in Huntington disease. Parkinsonism Relat Disord 15:471\u2013474","journal-title":"Parkinsonism Relat Disord"},{"key":"4444_CR272","doi-asserted-by":"publisher","first-page":"957","DOI":"10.2174\/1570159X18666201109090824","volume":"19","author":"S Vishwas","year":"2021","unstructured":"Vishwas S, Gulati M, Kapoor B, Gupta S, Singh SK, Awasthi A, Khan A, Goyal A, Bansal A, Baishnab S (2021) Expanding the arsenal against Huntington\u2019s disease-Herbal drugs and their nanoformulations. Curr Neuropharmacol 19:957\u2013989","journal-title":"Curr Neuropharmacol"},{"key":"4444_CR273","first-page":"559","volume":"44","author":"J-P Vonsattel","year":"1985","unstructured":"Vonsattel J-P, Myers RH, Stevens TJ, Ferrante RJ, Bird ED (1985a) Richardson Jr EPJJoN, Neurology E. Neuropathological Classification of Huntington\u2019s Disease 44:559\u2013577","journal-title":"Neuropathological Classification of Huntington\u2019s Disease"},{"key":"4444_CR274","doi-asserted-by":"crossref","unstructured":"Vonsattel J, Myers R, Stevens T, Ferrante R, Bird E, Richardson E (1985b) Neuropathological classification of Huntington\u2019s disease. Journal of neuropathology and experimental neurologY 44: 559\u2013577","DOI":"10.1097\/00005072-198511000-00003"},{"key":"4444_CR275","first-page":"2866","volume":"29","author":"DK Wilton","year":"2023","unstructured":"Wilton DK, Mastro K, Heller MD, Gergits FW, Willing CR, Fahey JB, Frouin A, Daggett A, Gu X (2023) Kim YAJNm. Microglia and Complement Mediate Early Corticostriatal Synapse Loss and Cognitive Dysfunction in Huntington\u2019s Disease 29:2866\u20132884","journal-title":"Microglia and Complement Mediate Early Corticostriatal Synapse Loss and Cognitive Dysfunction in Huntington\u2019s Disease"},{"key":"4444_CR276","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.cr.2019.01.001","volume":"8","author":"S Yan","year":"2019","unstructured":"Yan S, Li S, Li X-J (2019) Use of large animal models to investigate Huntington\u2019s diseases. Cell Regeneration 8:9\u201311","journal-title":"Cell Regeneration"},{"key":"4444_CR277","doi-asserted-by":"crossref","unstructured":"Yan S, Tu Z, Liu Z, Fan N, Yang H, Yang S, Yang W, Zhao Y, Ouyang Z, Lai CJC (2018) A huntingtin knockin pig model recapitulates features of selective neurodegeneration in Huntington\u2019s disease. 173: 989\u20131002. e1013","DOI":"10.1016\/j.cell.2018.03.005"},{"key":"4444_CR278","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.2174\/1570159X19666210915122820","volume":"20","author":"S Yang","year":"2022","unstructured":"Yang S, Zhu G (2022) 7,8-Dihydroxyflavone and neuropsychiatric disorders: a translational perspective from the mechanism to drug development. Curr Neuropharmacol 20:1479\u20131497","journal-title":"Curr Neuropharmacol"},{"key":"4444_CR279","doi-asserted-by":"crossref","unstructured":"Yang S-H, Cheng P-H, Banta H, Piotrowska-Nitsche K, Yang J-J, Cheng ECH, Snyder B, Larkin K, Liu J, Orkin J, Fang Z-H, Smith H, Bachevalier J, Zola SM, Li S-H, Li X-J, Chan AWS\u00a0(2008) Towards a transgenic model of Huntington\u2019s disease in a non-human primate. Nature 453:921\u2013924","DOI":"10.1038\/nature06975"},{"key":"4444_CR280","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1093\/hmg\/ddq313","volume":"19","author":"D Yang","year":"2010","unstructured":"Yang D, Wang C-E, Zhao B, Li W, Ouyang Z, Liu Z, Yang H, Fan P, O\u2019Neill A, Gu W (2010) Expression of Huntington\u2019s disease protein results in apoptotic neurons in the brains of cloned transgenic pigs. Hum Mol Genet 19:3983\u20133994","journal-title":"Hum Mol Genet"},{"key":"4444_CR281","doi-asserted-by":"publisher","first-page":"e49783","DOI":"10.15252\/embr.201949783","volume":"21","author":"P Yin","year":"2020","unstructured":"Yin P, Liu Q, Pan Y, Yang W, Yang S, Wei W, Chen X, Hong Y, Bai D, Li XJ, Li S (2020) Phosphorylation of myelin regulatory factor by PRKG2 mediates demyelination in Huntington\u2019s disease. EMBO Rep 21:e49783","journal-title":"EMBO Rep"},{"key":"4444_CR282","doi-asserted-by":"crossref","unstructured":"Yu M, Bega D (2019) A review of the clinical evidence for complementary and alternative medicine in Huntington\u2019s disease. Tremor and Other Hyperkinetic Movements 9","DOI":"10.5334\/tohm.509"},{"key":"4444_CR283","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1523\/JNEUROSCI.23-06-02193.2003","volume":"23","author":"Z-X Yu","year":"2003","unstructured":"Yu Z-X, Li S-H, Evans J, Pillarisetti A, Li H, Li X-J (2003) Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington\u2019s disease. J Neurosci 23:2193\u20132202","journal-title":"J Neurosci"},{"key":"4444_CR284","doi-asserted-by":"crossref","unstructured":"Yu Z, Yang W, Yan S (2024) Advantages and differences among various animal models of Huntington\u2019s disease. Ageing and Neurodegenerative Diseases 4","DOI":"10.20517\/and.2024.13"},{"key":"4444_CR285","first-page":"1131","volume":"25","author":"B Zeitler","year":"2019","unstructured":"Zeitler B, Froelich S, Marlen K, Shivak DA, Yu Q, Li D, Pearl JR, Miller JC, Zhang L (2019) Paschon DEJNm. Allele-Selective Transcriptional Repression of Mutant HTT for the Treatment of Huntington\u2019s Disease 25:1131\u20131142","journal-title":"Allele-Selective Transcriptional Repression of Mutant HTT for the Treatment of Huntington\u2019s Disease"},{"key":"4444_CR286","doi-asserted-by":"crossref","unstructured":"Zengin G, Yagi S, Eldahshan OA, Singab AN, Selvi S, Rodrigues MJ, Custodio L, Dall\u2019Acqua S, Ponnaiya SKM, Aly SH (2024) Decoding chemical profiles and biological activities of aerial parts and roots of Eryngium thorifolium Boiss by HPLC-MS\/MS, GC-MS and in vitro chemical assays. Food Biosci 104556","DOI":"10.1016\/j.fbio.2024.104556"},{"key":"4444_CR287","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1007\/s00415-023-11572-x","volume":"270","author":"S Zhang","year":"2023","unstructured":"Zhang S, Cheng Y, Shang H (2023) The updated development of blood-based biomarkers for Huntington\u2019s disease. J Neurol 270:2483\u20132503","journal-title":"J Neurol"},{"key":"4444_CR288","doi-asserted-by":"crossref","unstructured":"Zhu H, Barker P (2011) MR spectroscopy and spectroscopic imaging of the brain. Magn Reson Neuroimaging: Methods Protoc pp. 203\u2013226","DOI":"10.1007\/978-1-61737-992-5_9"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04444-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04444-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04444-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T05:02:34Z","timestamp":1764824554000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04444-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":288,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4444"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04444-w","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,17]]},"assertion":[{"value":"6 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal ethics declaration"}}]}}